|
Monitoring Stem Cell Research
The President's Council on Bioethics
Washington, D.C.
January 2004 www.bioethics.gov
Pre-Publication Version
Chapter Three
Recent Developments in the Ethical and Policy Debates
The announcement of the Bush administration's human embryonic
stem cell research funding policy in the summer of 2001
certainly did not end the debates surrounding the issue.
The policy offered a particular target to which participants
in the debate could react, but the basic questions involved
in assessing how the federal government should approach
embryonic stem cell research remained just as relevant,
and just as controversial, as they had been before. In this
chapter, we offer an overview of that still continuing debate
as it has developed in the past two years. Without attempting
to provide anything like a full account of different positions
and arguments, we hope, rather, to point to the major items
under argument-to the issues that any interested citizen
might wish to ponder. First, we will outline the general
form of the moral argument as it has developed over time.
Second, we will discuss specific questions and critiques
regarding the current policy, as those have emerged in public
discussion. Third, we will review the various positions
on the moral standing of human embryos, seeking again to
outline the chief fault lines in that continuing debate.
And finally, we will highlight some critical ethical concerns
that do not arise directly out of the debate over the moral
standing of human embryos but which may be no less important
to the larger question confronting the country.
This array of subjects includes both some that are clearly
ethical questions and some that may fall closer to questions
of policy. We take up both together because we believe both
are essential to a full understanding of the issues involved
and because even the policy debates-as understood and engaged
in by participants on all sides-are clearly directed to
a set of underlying moral issues and informed by ethical
beliefs and opinions. Critiques (and defenses) of the present
policy, and proposals of alternatives, are almost without
exception based on moral grounds.
This chapter will, of course, revisit several of the themes
raised in the previous chapter. There, our aim was to present
some basic facts regarding the current policy, its context,
and its execution. Here, we take up arguments on all sides
of the issue-including those that dispute the understanding
of the policy put forward by its authors and those that
raise other issues or alternative courses of action.
While we will raise these arguments and counterarguments,
examining problems, questions, and concerns, our purpose
is not finally to assess the validity of the competing claims
or to arrive at a conclusion, but-in line with the Council's
charge to monitor developments in this area-to present them
more or less as they have appeared in the public debates
of the past several years. This way of proceeding suffers
from one especially prominent drawback: it tends to present
all arguments as equal in importance or prevalence. We will
seek to avoid this whenever possible, by offering some sense
of which arguments have been most crucial for the public
debate.
I. The Nature of the Moral Argument
Before entering upon a detailed review of the debates,
we take a moment to consider the character of the
moral reasoning and argumentation we will confront. Different
participants in the stem cell debates tend to hold different
views not only regarding individual substantive judgments,
but also regarding the kind of moral question, in the most
general terms, we are facing in deciding about stem cell
research policy. At first glance, people seem to be disagreeing
about whether a balancing of competing interests and goods
is called for, or whether some one overriding moral duty
ought to shape our judgment, though of course that dichotomy
is not in every case quite so stark.
In casual conversation, and sometimes in more theoretical
reasoning, moral questions are often analyzed in the language
of "weighing" and "balancing," or else in terms of overriding
concerns, inviolable principles, or fundamental "rights."
These two sets of terms and metaphors point to two distinct
ways of making difficult moral judgments. In some circumstances
there need be no irresolvable conflict between the two approaches.
Those who seek to respect fundamental rights and adhere
to inviolable principles need not ignore the complexities
of moral situations or the consequences of our actions when
they form their judgments. Likewise, those who seek to weigh
or balance competing goods may think of those goods as involving
not only benefits to be realized but also principles to
be upheld. There may also be circumstances, however, in
which those differences that do exist between these two
approaches constitute a fork in the road, constraining our
decision. Thus, to take an example from outside the domain
of bioethics, the principle that civilians should be safeguarded
from direct, intended attack in time of war may be understood
to trump all other competing goods (without denying the
importance of those goods), or it may be understood as one
good to be balanced against others. Which fork in the road
of moral reasoning one takes at such a point will have a
decisive influence on the character of the arguments employed
and the conclusions reached.
This has often also been the case in the public debate
over federal funding of human embryonic stem cell research.
Many observers have agreed that federal policy must seek
a certain balance between two competing goods or interests:
the progress of medical research and therapy, and respect
for nascent human life. Indeed, President Bush himself framed
the issue in these terms, saying a few weeks before his
decision was announced that his policy would "need to balance
value and respect for life with the promise of science and
the hope of saving life."1
But not all participants in the debate have had the same
idea of what such balance should entail and, therefore,
how weight should be assigned to the competing demands.
For some, the degree of medical promise should profoundly
affect the degree of government support for embryonic stem
cell research. For them, the critical element (though of
course not the exclusive one) in establishing policy must
be scientific data about what might be achieved with human
embryonic stem cells.2
The greater the promise of the research, the more support
it should receive and the more it should outweigh reasons
offered for opposing the techniques involved.3
On this view, the concern given greatest prominence and
weight in reaching a judgment ought to be the very great
good of medical progress toward the relief of suffering.
Most of the arguments in favor of increased taxpayer funding
of embryonic stem cell research have begun from this premise-explicitly
or implicitly-and have proceeded by laying out the possible
medical benefits of the research or the possible harms (to
patients or to American science) of withholding support.
We shall review a number of these lines of argument in more
detail below. But it is worth noting at the start that most
of them tacitly assume that the policy decision at hand
ought to be based on a reasoned balancing of crucial concerns-all
of which matter but none of which simply overrides the others.
Others, however, have suggested that at least a substantial
portion of the opposition to the research rests upon the
belief that human embryos should not be violated and therefore-if
this claim is valid-that the threat to their life and worth
cannot be justified by the promise of research.4
It follows, on this view, that the federal government should
do nothing to encourage or support the future destruction
of human embryos, regardless of the promise of research.
What remains then to be considered is the extent to which
the government might advance the additional aim of progress
in medical research within the bounds of the principle.5
In this case, the moral reasoning is understood
to be decisively affected by an unbreachable boundary, and
only the extent of some particular provisions of the policy
are left to be settled by a weighing and balancing of other
priorities. Proponents of the various forms of this position
generally argue that the claim of human embryos to our protection
presents us with a fundamental duty, to be overridden, if
at all, only in extreme circumstances, rather than with
just one good to be balanced off against others.6
In presenting the matter this way, adherents of this view
consciously appeal to the ethics governing research with
human subjects, which obliges those engaged in efforts to
advance knowledge and seek cures to keep from trespassing
upon human safety, freedom, and dignity.7
The decades-old and nearly universal adherence of researchers
to rules protecting human subjects, these commentators suggest,
demonstrates that the needs of research are not always treated
as paramount and that the scientific community itself joins
the general public in recognizing instances in which research-however
important-must be limited for ethical reasons.8
Researchers do not weigh the interests of human subjects
against the importance of their work; rather they respect
a principled boundary-that human subjects are not to be
harmed or put at risk without their informed consent-the
importance of which trumps even the most promising experiment.
For some defenders of human embryos, the prospect of embryo
research raises precisely these concerns; accordingly, they
argue that this issue too should be decided on the basis
of a moral rule, not by a shiftable tally on a balance sheet
of benefits.9
But this assertion about the proper form of moral argument
depends on the truth of the claim that human embryos are
indeed human subjects of research. Therefore, one's position
in the debate about the basic character of the moral issue
may depend, in many cases, on one's understanding of the
moral standing of human embryos. As we shall see, the question
of the moral standing of embryos is by no means the only
relevant question. But in the actual public debate, as it
has developed, this question seems to have been most central
and prominent and probably most responsible for shaping
the different basic approaches pursued. It is this question
that very often informs the differing views regarding which
aims or goods are more weighty or which should not be compromised
at all.
We turn next to arguments regarding that very issue: Which
moral aims or which concerns should be given priority in
shaping government policy toward human embryonic stem cell
research?
II. The Moral Aims of Policy
A significant part of the public debate surrounding the
policy governing funding of embryonic stem cell research
has involved differing views of just which purposes or ideals
should most directly guide policymakers in this arena. The
current funding policy-while it appears to strike some balance
between protecting human embryos and advancing biomedical
research-seems to take as its overriding concern the insistence
that the federal government not encourage or support the
deliberate violation or destruction of human embryos. But
a number of commentators in recent years-and, of course,
particularly those who ascribe lesser moral status to human
embryos-have proposed alternative principles to govern policy.
A. The Importance of Relieving Suffering
Many observers argue that the proper governing principle
should be the duty to relieve the pain and suffering of
others-the purpose that ultimately motivates the work of
biomedical science. This aim is broadly, perhaps universally,
shared. Indeed, the current policy, as outlined by its advocates,
while it seeks to protect nascent human life, explicitly
seeks to advance medical research as far as its authors
believe is morally permissible. Some commentators argue,
however, that the administration has chosen the wrong one
of these aims as the governing principle of its approach.
The cause of curing disease has a human face, the face
of a loved one or neighbor, bent under the suffering of
an incompletely understood or treated disease. As a result,
the aspiration to know is linked to a desire to relieve.
How, wonder many commentators, could anyone think of withholding
support for research that might yield therapies for devastating
diseases and conditions such as spinal cord injury, diabetes,
and Parkinson disease?10
Surely, they argue, the pain and suffering of those in need
should outweigh concerns for human embryos frozen in a laboratory.11
Indeed, for many this is an especially critical issue in
light of the likely ultimate fate of these embryos. Will
they be frozen indefinitely? If not, then will they be thawed
out and discarded and destroyed, or used to potentially
benefit mankind?
One form of this argument, heard increasingly over the
past few years, begins with data about disease prevalence
and suggests that anyone who obstructs public funding of
research that might someday help patients suffering from
such diseases must bear some of the responsibility for their
future suffering and (perhaps) death.12
Some opponents have countered that any assertion that makes
relief of human suffering the highest moral principle to
this extent might logically impugn any and all deflection
of resources into less ultimate concerns such as recreation,
beautification, or social ceremony. Others respond more
directly that an unwillingness to violate one's moral principles
in order to help relieve the sick does not make one responsible
for their sickness.13
In most cases, however, the arguments for grounding federal
funding policy in the importance of biomedical research
do not blame opponents for the suffering of the sick. Rather,
they focus on the promise of bringing relief to those who
most need it. They point to the immense benefits already
delivered to us by modern medicine and argue that the federal
government should advance this cause in whatever ways it
reasonably can. Many advocates of this view agree that nascent
human life should receive respectful treatment, but they
argue that the claims of our duties to human embryos-whether
in general or in particular circumstances, like those stored
in fertility clinic freezers-cannot simply trump the claims
of promising medical research and our duties to suffering
humanity. The obligation to aid the sick, they contend,
and the fact that the research in question might relieve
the pain and terrible suffering of countless patients and
their families, should lead us to do all that can reasonably
be done to find treatments and cures, and to offer help.
This does not mean simply ignoring the significance of human
embryos, or taking lightly the decision to destroy them
in research, but, they suggest, it should mean taking seriously
the moral calling to help the suffering, and deciding how
to proceed based on more than one sort of obligation.14
In response, one commentator has argued in broad terms
against the underlying assumption that the demands of biomedical
research should somehow be seen as "imperative." Such work,
he contends, should not be seen as inherently and always
obligatory, and claims to support it may be overridden even
by a level of respect for nascent human life that does not
suppose that embryos possess full human moral standing.
He suggests that it is not at all obvious that individuals
or the government have a definite responsibility to support
such research or that such a responsibility would override
other moral duties.15
Others point out that the duty to find cures for disease
cannot be an unqualified or absolute imperative. Pointing
to the present rules governing the treatment of human subjects
in research, they argue that the case for embryonic stem
cell research cannot rest on an alleged and overriding imperative
to pursue that research. These rules prohibit certain sorts
of procedures on human subjects of research; and the same,
they suggest, should be required in stem cell research.
Yet those who argue that the importance of medical research
and treatment should override the aim of protecting human
embryos presumably would not propose to override protections
for human subjects in research on children or adults. Rather,
they approach the present matter differently because they
do not consider human embryos the developmental, anthropological,
or moral equivalent of children or adults, or worthy of
the same protection. The difference, therefore, has to do
not so much with a dispute over the imperative importance
of research, but rather (at least to a significant extent)
with the status of nascent human life, which again turns
out to be the fundamental point at issue.17
Nevertheless, the moral claims of medical research and
treatment are extremely powerful in the debate over human
embryonic stem cell policy, and they are acknowledged as
profoundly important even by those who do not finally take
them to be decisive. Most arguments in opposition to the
present funding policy and in support of expanded embryonic-stem
cell research are grounded in these claims.
B. Freedom to Conduct Research
Other opponents of the present policy argue not from the
value of medical benefits but on the basis of freedom to
conduct research, which they believe is the principle by
which federal policy ought to be governed. They regard government
restraints on scientific research as inherently offensive
and generally unjustifiable.17
The cherished ideals of freedom of thought, freedom of conscience,
and-specifically in this context-freedom of inquiry, trump
concerns over the moral status of human embryos, they contend.18
The most common claim advanced for protecting research
as a basic right (employed, among others, by the American
Bar Association) involves some form of an appeal to the
First Amendment's protection of free speech, interpreted
through the years by the Supreme Court to encompass free
expression and perhaps freedom of inquiry and thought.19
Some argue that research is a form of expression, particularly
when it is politically or socially controversial, and when
restraints upon it are imposed for moral reasons.20
"One could make the case that research is expressive activity
and that the search for knowledge is intrinsically within
the First Amendment's protection for freedom of thought,"
says one ethicist.21
Others, however, contend that this claim, never tested
in the courts, seems far-fetched. Most currently controversial
biological research involves experimental manipulation of
living matter, rather than theoretical exploration or mere
observation of natural objects. It is therefore as much
action as expression, as much creation as inquiry. It is
difficult to see, they argue, how such activity (as opposed
to the reporting of the results of such activity) could
be classified as a form of expression. "Scientists may have
the right to pursue knowledge in any way they want cognitively,
intellectually," argues one observer, "but when it comes
to concrete action in the lab, that becomes conduct and
the First Amendment protection for that is far, far weaker."22
Moreover, argues at least one commentator, even if one
did stipulate that research activity is to be protected
from governmental proscription or restriction, it is far
from clear that failure to provide federal funding would
constitute such a restriction.23
Indeed, legislative and judicial precedents
suggest it would not. The government routinely refrains
from funding activities it otherwise permits or even guards
as constitutionally protected. A line of Supreme Court decisions
stretching from 1977 to 1991, dealing with abortion and
government funding, established the principle that the Constitution
does not require the government to fund even those activities
that the Constitution protects.24
Because the only issue in the present debate is one of federal
funding, the protected status of scientific activity seems
not to be a determining factor.25
Finally, some critics of the case for a paramount right
to research point again to the fact that scientific research-conducted
both with private and (especially) with government funding-is
already subject to certain restrictions, particularly with
regard to protecting human subjects. The proposition that
embryo research should not be subject to the same restrictions
hinges on an argument about the standing of human embryos,
rather than about the unrestrictable standing of research
as such.26
Once more, an important part of the question turns on the
status of extra-uterine human embryos.
C. The Moral Standing of Human Embryos
However they approach the matter, then, many people engaged
in the debate over federal funding policy find they must
consider the fundamental question of the moral standing
of human embryos: What are early human embryos, and
how should we regard them morally? Approaches to the question
of federal funding of embryonic stem cell research that
propose some other guiding principle-relief of suffering,
freedom of research-seem almost by necessity to assume that
human embryos do not possess the same human moral standing
as persons already born.27
Conversely, if human embryos ought rightly to be treated
as inviolable-as some have argued-then questions of balancing
other goods or giving priority to other principles are largely
rendered moot. Thus, to many observers, some of the central
questions in this arena would appear to be those that surround
human embryos: How ought we to think about and act toward
human embryos? Should all ex vivo human embryos be treated
the same, or are some, because of their circumstances, origins,
or prospects, to be treated differently from others? Or
are embryos of sufficiently little moral significance that
we should simply decide the funding question solely on the
basis of the merits and promise of the proposed biomedical
research?
We shall, in due course, review the recent arguments on
these critical questions. But before doing so, we examine
a series of other more specific objections to the present
policy. These arguments recognize that the current policy
rests on the conviction that federal funds should not support
or encourage the violation or destruction of human embryos.
Rather than disputing this premise, a number of commentators-including
both supporters and critics-have assessed the policy on
its own grounds and judged it against its own claims and
terms. As a result, several general categories of criticism
of the policy itself have emerged.
III. The Character of the Policy
In addition to debating which aims ought to guide federal
policy, many observers in the past two years have also assessed
the particulars of the present funding policy, considering
them in scientific, political, and moral terms. Critics
have generally found fault with the policy through one or
more of three general lines of argument: that it is arbitrary,
that it is unsustainable, and that it is inconsistent. Defenders
of the policy, meanwhile, have usually sought to counter
these critics on these terms and to rebut these assertions
and criticisms.
A. Arbitrary
One quite common line of argument criticizes the present
funding policy as essentially arbitrary, because it relies
on what is deemed a capricious cutoff date. Cells derived
from embryos destroyed on August 9, 2001 are eligible for
federal funding, but those obtained from embryos destroyed
the next day are not. The only difference is the date of
embryo destruction, argue some critics, and what moral difference
could that possibly make? If the policy of funding human
embryonic stem cell research serves a genuine good, these
commentators suggest, would it not be equally good regardless
of when the cell lines were derived? Would it not, therefore,
make sense to permit funding for all cell lines derived
on either side of the date, provided they are otherwise
eligible?28 If,
on the contrary, federal funding of embryo research is unacceptable,
then it should simply not be allowed at all, regardless
of when cell lines were first derived.29
"It is difficult to see," writes one critic, "what ethical
reasoning would commend a policy that takes as its central
distinction the time chosen for political convenience to
deliver a presidential address."30
In response, some supporters of the policy contend that
while the cut-off date (August 9, 2001) certainly has no
inherent moral significance, it acquires moral meaning by
the simple fact that it was the operative date of a newly
announced policy that turned on a crucial distinction between
the "up-until-now" and the "from-now-on," between past (irrevocable)
deeds and future (preventable) ones. That date of announcement
was the line between past embryo-destruction, which could
no longer be undone, and future embryo destruction, which
could still be influenced by the federal government's funding
rules. If the policy sought to avoid encouraging or offering
incentives for any future destruction of human embryos,
they argue, then drawing a hard line between past and future
would be indispensable. That line could only reasonably
be drawn at the moment of the decision's announcementi
(or before it), since drawing it at some point in the future
would create a powerful incentive to quicken the pace of
work until the cut-off date arrived. The date, they say,
is therefore not a morally arbitrary marker in the context
of the policy, but is rather a crucial and unavoidable element
of the policy's logic.31
B. Unsustainable
A further, and more common, critique of the current policy
suggests that its approach cannot be expected to hold over
time and that it will fairly quickly prove unsustainable.
One form of this argument suggests that the policy has
created a situation in which scientists may make some progress
using existing stem cell lines but would then be prohibited
from capitalizing on what they have learned and making further
progress using stem cell lines not now eligible for federal
funds. As the editors of the Washington Post put
it: "Mr. Bush's compromise policy will be a reasonable one
only as long as the existing lines are capable of supporting
the research scientists need to perform."32
Indeed, some have argued that by explicitly encouraging
and speaking of the potential medical value of human embryonic
stem cell research, the President himself created the circumstances
that will make the constraints of the policy unsustainable.
"Bush's decision was at its core an endorsement of the promise
of human embryonic stem cells and their importance to the
fledgling field of regenerative medicine," wrote one critic,
and if that is the core message of the decision, then the
resulting policy seems insufficient.33
Others, arguing on more practical grounds, claim that,
regardless of the reasonableness of the principle behind
the policy, its effects will prove unbearable for American
scientists, who will then force a reconsideration.34
The limits placed on funding in the current policy, several
observers have predicted, will seriously hamper and hold
back embryonic stem cell research work in the United States,
perhaps causing prominent scientists to leave the country
in search of greater support abroad.35
If that were to occur, it is argued, the policy would prove
genuinely damaging to American science, and therefore to
the national interest, and would need to be changed.36
In response to this specific point, some defenders of the
policy have noted that for the time being there has not
been news of any notable migration of prominent stem cell
researchers to foreign countries, that federal funding is
now available with no ceiling on its amount, and that American
researchers can continue to work with private funds.37
But even apart from worries about a "brain-drain" in the
field, some have argued that both the lack of funding, and
particularly the complexity of the set of conditions under
which research using such funding may be conducted, is preventing
progress in research and discouraging even private funding
in the field,38
and that the lines made available simply will not be enough,39
or indeed that they have already proved insufficient.40
Some argue that the very low number of applications submitted
to the NIH for postdoctoral and training projects using
the approved stem cell lines provide striking evidence for
the chilling effect of the current "in limbo" situation.
Some have also suggested that safety issues connected with
the way the eligible lines have been derived and developed
may make them less suitable for use in human trials and
treatments, thus making other cell lines necessary (although
presentations before this Council by NIH Director Elias
Zerhouni and FDA Commissioner Mark McClellan have contradicted
some of these claims).41
Others, meanwhile, worry that the eligible lines do not
offer sufficient genetic diversity to be adequate for research
needs or for eventual therapies.42
As scientists make their case that important work is being
hampered, it is argued, the policy will prove unsustainable
politically and practically.43
A similar argument has also been made in nearly the opposite
terms. That is, some have said that if or when ongoing embryonic
stem cell research produces a spectacular breakthrough in
understanding or treating disease, the pressure to alter
the policy would prove unstoppable.44
This way, whether the future brings announcements
of great progress, or whether it brings no news of advances,
the result will be pressure for a policy that funds research
more broadly.
Those defenders of the policy who have addressed these
claims of unsustainability have pointed out that the present
policy does not limit the amount of federal funds
available to the kind of research that may be performed
with the approved cell lines. They also point out that much
of the pioneering work in mouse stem cell research was done
using very few (approximately 5) cell lines45
(though of course the challenge of working with human cell
lines is more complex and daunting). But they have also
generally pointed to the policy's stated grounding in principle-a
principle that would not change in light of scientific advances
or delays. In August of 2001, for instance, Health and Human
Services Secretary Tommy Thompson told reporters that "neither
unexpected scientific breakthroughs nor unanticipated research
problems would cause Bush to reconsider" the approach drawn
by the policy, because it is based on "a high moral line
that this president is not going to cross."46
As another observer has put it: "The general
question is, well, will these cell lines be enough . . .
and a non-complicity argument [like the one implied by the
policy] will only work if the answer to that question is
well, I guess they'll have to be enough."47
Or, put differently, if the policy is founded primarily
in a determination to prevent government funds from encouraging
the destruction of human embryos, and only secondarily in
a judgment about the value of embryonic stem cell research,
then advances in research alone (or the absence of advances
alone) would not be sufficient to overturn it. If it is
sound before such advances, some argue, it would still be
valid after48-though
again, of course, whether it is right to begin with is itself
a point of great contention.
C. Inconsistent
In responding to critiques like those just discussed, defenders
of the administration's policy generally point to the principles
that define the approach of the policy, as partially laid
out in the previous chapter. But some criticism of the policy,
directing itself precisely to the claim of consistent adherence
to principle, has charged that the policy is morally contradictory,
or at least inconsistent, in its own terms.
One common form of the charge of inconsistency concerns
the distinction the policy tacitly draws between public
and private funding. The current policy addresses itself
only to federal funding of embryo research and is silent
on the conduct of such research in the private sector. But
the source of funding, this line of criticism suggests,
could have no bearing on the question of the moral status
of human embryos or the propriety of using them in research.
If federal funding for research that destroys human embryos
is so troublesome, then why should such research be allowed
to proceed when privately funded? Acting to restrict one
but not the other may be prudent, but it seems inconsistent.49
Indeed, by implicitly excluding such research from federal
guidelines, it may actually encourage more reckless practices
and may simply transfer the problem of complicity to the
private sphere, where it is even more difficult to monitor
and moderate the uses to which human embryos are put. Though
these critics understand that the President cannot simply
ban embryo research by himself, they argue that he could
attempt to convince the Congress to do so, and he could
have made such an attempt as an element of his funding policy
decision. But he did not-thus bringing into question (for
these critics) not only his commitment to the principle
articulated by the policy, but also his own view of the
moral standing of human embryos, which the policy itself
does not make simply apparent.50
Moreover, critics argue, some prominent defenders of the
policy, by making the fact of ongoing private research an
element of their defense, might be said to contribute to
these doubts about its grounding in consistent principle.51
There may be some political or structural reasons for drawing
a distinction in federal policy between what is funded and
what is permitted. Questions of federalism and other legal
realities no doubt enter the picture, and indeed those who
oppose the destruction of human embryos are, in many cases,
actively seeking prohibitions on all embryo research in
individual states.ii
But, critics point out, they generally say little on the
larger question of permissibility at the federal level.
By making funding the center of concern, these critics argue,
the policy puts into question the importance of preventing
embryo destruction more generally, casting some uncertainty
over the relation of that policy to one or another position
regarding the moral standing of early human embryos.
A related criticism contends that the distinction drawn
between research practices in which human embryos are destroyed
and research practices that use the products of previous
embryo destruction is itself inconsistent-a distinction
without a difference, drawn for political cover.52
"Pretending that the scientists who do stem cell research
are in no way complicit in the destruction of embryos is
just wrong, a smoke and mirrors game," writes one critic.
"It would be much better to take the issue on directly by
making the argument that destroying embryos in this way
is morally justified-is, in effect, a just sacrifice to
make."53
Similar objections have also been raised by critics on the
other side of the embryo question, who believe that embryo
destruction is morally unjustified and that the present
policy does not sufficiently distance the federal government
from such destruction. "The federal government, for the
first time in history, will support research that relies
on the destruction of some defenseless human beings for
the possible benefit to others," one critic contended in
the immediate wake of the August 9, 2001 announcement. "However
such a decision is hedged about with qualifications, it
allows our nation's research enterprise to cultivate a disrespect
for human life."54
A further critique of the policy on grounds of inconsistency
focuses more particularly on specific elements of the implicit
claim to non-complicity, discussed in the previous chapter.
If, as many of its advocates argue, the policy takes embryo
destruction to be essentially a morally unjustifiable act,
and if its provisions aim to make use of the irreversible
consequences of that act without in any way encouraging
or abetting the act itself, then, critics contend, it is
curious that the policy would insist on requiring (in addition)
that the eligible stem cell lines must have been obtained
from embryos originally intended for reproduction and used
with donor consent and without financial inducements. If
embryo destruction is in principle a wrong, and if the policy's
provisions seek only to keep the federal government from
complicity in that wrong, then why should it matter how
precisely the wrong was originally committed? The presence
of these conditions, it is argued, suggests that the policy
is not in fact based in a consistent and principled adherence
to the proposition that human embryos should not be destroyed.
Indeed, some have argued that this character of the policy
suggests that its authors, including the President, may
not hold the view that human embryos deserve the same protections
as human children or adults. These critics suggest not so
much that the current policy is necessarily inconsistent,
but that it may only be consistent with a view of human
embryos as possessed of intermediate or indeterminate moral
standing, rather than a view which holds that human embryos
ought simply not to be destroyed for the benefit of others.55
In response to these last arguments, some have suggested
that the qualifying conditions included in the policy reflect
a secondary commitment to long-standing principles of human-subject
and embryo research and a recognition of pre-existing standards
in such research, rather than a contradiction of the fundamental
commitment to avoiding any support for the destruction of
nascent human life. The government, they argue, has multiple
aims in this area, and these need not undercut each other.
In addition to discouraging the creation and use of embryos
for purposes other than producing children, one commentator
argues, the government also seeks to support the requirement
for informed consent to all procedures involving human subjects
and to discourage commercial trafficking in human material.56
Another observer has suggested that the additional conditions
are an expression of the fact that some standards for stem
cell derivation did exist before August 9, 2001, including
those reflected in the Clinton administration's funding
guidelines.57
Even in rejecting the legitimacy of the act of embryo destruction
and seeking to discourage it in the future, it is still
reasonable to recognize the value of those earlier standards.
The policy, it is argued, while establishing a new standard,
still takes account of previous standards.58
In response to the more general complaints of inconsistency,
defenders of the policy, within and outside the administration,
have described the present policy as both principled and
prudent. The policy, as articulated by these defenders,
aims (at least minimally) to uphold and advance the principled
conviction that the federal government should not offer
support or incentives for the destruction of nascent human
life for research. At the same time, they say, it seeks,
as much as reasonably possible within the bounds of the
principle to benefit from the results of embryo destruction
that has already occurred and can no longer be undone.59
As President Bush put it in announcing the policy, "This
allows us to explore the promise and potential of stem-cell
research without crossing a fundamental moral line, by providing
taxpayer funding that would sanction or encourage further
destruction of human embryos that have at least the potential
for life."60
The policy, argue some of its advocates, aims to put into
practice the moral principle of not destroying nascent human
life, even if it does not do so on every possible front,
or to the greatest possible extent.
Regarding the alleged inconsistency of withholding federal
funding but not calling for a ban on all private embryo
research, some have pointed out that the Dickey Amendment,
under which the President was acting, is itself a "don't
fund, don't ban" law. Moreover, they argue that neither
statesmanship nor prudence requires that the President do
battle with what is settled practice (the free use of embryos
in private-sector research) or push zealously against everything
to which he is morally opposed, especially in a pluralistic
society that is deeply divided on the moral issue. An analogous
case may be found in the administration's approach to abortion,
a practice that the President says he opposes deeply on
moral grounds: the administration supports the legislative
ban on federal funding, but has not called for a constitutional
amendment that would ban abortion. As President Bush told
the pro-life "March for Life" participants in January 2002:
"Abortion is an issue that deeply divides our country. And
we need to treat those with whom we disagree with respect
and civility. We must overcome bitterness and rancor
where we find it and seek common ground where we can. But
we will continue to speak out on behalf of the most vulnerable
members of our society."61
In a similar way, its defenders contend that the current
administration policy on stem cell research funding keeps
the public ethical conversation open, may be acceptable
to some individuals who hold that human embryos possess
an intermediate or unknowable moral standing, and, at the
same time, also advances the cause of those who contend
that human embryos should be protected from destruction
altogether.62
The present funding policy has also been defended from
the charge of inconsistency on rather different grounds,
which, for their advocates, carry different consequences
for future federal funding. This defense contends that,
if the early embryo is morally equivalent to a child, then
the proper moral response would be to ban all future embryo
destruction and all stem cell research (public and private)
on embryos destroyed after August 9, 2001, and not merely
deny it federal funding. Confronted with a practice that
involved killing children so that their organs could be
used to save the lives of others, advocates of this view
contend, no one would simply deny it federal funding while
allowing the gruesome practice to continue. But, they point
out, there is no reason to attribute to the current funding
policy the assumption that the early embryo is morally equivalent
to a child. In fact, they contend, the President has never
said that early embryos are inviolable, or are persons,
or morally equivalent to children. While President Bush
explained his funding policy by arguing that "it is unethical
to end life in medical research,"63
he has not sought to prohibit privately-funded embryonic
stem cell research. This leads some to conclude that implicit
in the President's policy is either the view that the embryo
has an intermediate moral status (worthy of serious moral
consideration as a developing form of human life) or uncertainty
about its moral status. Those who interpret the President's
policy in this way point out that, in his address to the
nation on stem cell research, he spoke in terms of a human
embryo's "potential for life":
Research on embryonic stem cells raises profound ethical
questions, because extracting the stem cell destroys the
embryo, and thus destroys its potential for life. Like a
snowflake, each of these embryos is unique, with the unique
genetic potential of an individual human being. 64
This, they contend, does not constitute an argument for
treating human embryos as possessed of fully human moral
standing.65
If the present policy is seen to reflect either the intermediate
or uncertain view of the moral standing of human embryos,
these advocates argue, it is not inconsistent to withhold
federal funding, at least for now, when the medical benefits
of stem cell research are still speculative, while permitting
privately funded embryo research to proceed. They argue
that restricting or limiting federal funding is a reasonable
way of registering either doubt about the moral status of
the embryo, or the moral unease felt by someone who takes
nascent human life seriously and does not want it used wantonly,
and who therefore wants scientists to prove the promise
of this research before permitting them to go further with
the support of federal funding. Indeed, they argue, this
interpretation is consistent with the President's words
in his August 9th address:
[W]hile we're all hopeful about the potential of this
research, no one can be certain that the science will live
up to the hope it has generated. . . . Embryonic stem cell
research offers both great promise and great peril. So I
have decided we must proceed with great care." 66
Viewing the administration's policy as based on an intermediate
or uncertain view of the moral standing of human embryos
also makes plausible, in the view of these observers, the
fact that the President has neither called for a ban on
privately funded embryo research, nor called upon scientists
to desist from research on stem cell lines created after
August 9, 2001. They contend that it also makes sense of
the requirements, discussed above, that stem cell lines
created before that date must, in order to qualify for federal
funding, be derived from excess embryos created for reproduction,
with donor consent, and without financial inducements.
Those who interpret the policy as reflecting an intermediate
or uncertain view of the moral status of human embryos argue
further that, if embryonic stem cell research vindicates
its promise, there would be no categorical reason to prevent
a reconsideration of federal funding in the light of medical
advances. A further implication is that people may reasonably
draw different conclusions about whether this principle
justifies federal funding of stem cell lines derived after
August 9, 2001 provided they are derived from embryos left
over from IVF procedures, donated with consent, and without
financial inducement.67
Although the President has declared that he regards destructive
embryo research as unethical without additional qualifications,68
and although HHS Secretary Tommy Thompson has said that
scientific advances would not cause the President to reconsider
his policy,69
those who interpret the President's policy as reflecting
an intermediate or uncertain view of the embryo argue that
the moral logic of this principle admits the possibility
that significant medical breakthroughs could justify a reconsideration.
IV. The Moral Standing of Human
Embryos
Many elements (though, as we shall make clear, not all
elements) of the ongoing debate about federal funding of
human embryonic stem cell research seem, as we have reviewed
them, to turn on a basic disagreement about the nature,
character, and moral standing of human embryos. Public debate
over the moral standing and appropriate treatment of human
embryos has been quite contentious and divisive in recent
years. In part, this had to do with its almost inevitable
entanglement with the abortion debate, itself a deep and
thorny controversy in America. In part, too, this has been
connected to the fact that the question of the moral standing
of human embryos touches many other fundamental moral and
existential questions involving human origins, human dignity,
the moral significance of our biology, and its relation
to numerous traditional and widely shared moral teachings.70
Differences of opinion on the moral standing of human embryos
often suggest differences on these larger questions of overall
worldview.71 Nonetheless,
the question of the moral standing of human embryos itself
has been taken by nearly all commentators to be amenable
to human reason and argument, and a lively debate has raged
despite (or perhaps precisely because of) these widely diverging
starting assumptions.
In the public arena, the question of the moral standing
of human embryos has often been summed up in the question,
"When does (a) human life begin?" This question suggests
something of the quandary, although the academic and intellectual
debate generally takes a somewhat more nuanced question
as its starting point. That question has as its unstated
premise the fact that under normal circumstances we regard
all born human beings (from newborns through adults) as
possessing equal moral worth and meriting equal legal protection.
It then reflects upon the ways in which human embryos are
similar and different from live-born human individuals,
the moral significance of those similarities and differences,
and therefore whether embryos should or should not be afforded
protections.72
The first and most common recourse in seeking an answer
to such questions has been human biology, and particularly
human embryology. Nearly all participants in the dispute
make some reference to biological findings, whether to claim
that they teach us about an embryo's essential continuity
with and similarity to human beings at other stages of life,
or to argue that they reveal profound and morally meaningful
discontinuities between embryos and live-born persons.
While we examine these differing contentions, it is crucial
to remember-as several commentators in recent years have
noted-that the biological findings, however relevant, are
not themselves necessarily decisive morally.73
They may serve better to challenge moral
positions founded on erroneous assumptions than to ground
some positive moral affirmation or conclusion. For example,
a recognition of biological continuity might in some measure
undermine the argument that embryo destruction is permissible
when certain biological markers or states of development
are absent. But it would not by itself show indisputably
that embryos are to be treated as simply inviolable.74
Meanwhile, recognizing the biological significance
of some particular point, marker, characteristic, or capacity
would not, in itself, imply some decisive moral significance.
A description of early embryonic development is necessary
though not sufficient to an understanding of the nature
and worth of an early embryo.75
It is not sufficient because any purely biological description
requires some interpretation of its anthropological and
moral significance before it can function as a guide to
action.76
With these provisions in mind, we offer the following brief
review of developments in the debate over the moral standing
of human embryos in the past several years.iii
A. Continuity and Discontinuity
Many participants in the debate take the question of the
biological continuity or discontinuity between nascent and
later human life to be crucially significant. Some argue
that the fundamental organismal continuity from the moment
of fertilization until natural death means that no lines
can be drawn between embryos and adults. Others argue, on
the contrary, that some particular point of discontinuity
(or the sum of several such points) marks a morally significant
distinction between stages, which difference should guide
our treatment of human embryos.
1. The Case for Continuity.
Many of those who seek to defend human embryos base their
case on some form of the argument for biological continuity
and sameness through time. For example, they argue that
a human embryo is an organic whole, a living member of the
human species in the earliest stage of natural development,
and that, given the appropriate environment, it will, by
self-directed integral organic functioning, develop progressively
to the next more mature stage and become first a human fetus
and then a human infant. Every adult human being around
us, they argue, is the same individual who, at an earlier
stage of life, was a human embryo. We all were then, as
we still are now, distinct and complete human organisms,
not mere parts of other organisms.77
This view holds that only the very beginning of a new (embryonic)
life can serve as a reasonable boundary line in according
moral worth to a human organism, because it is the moment
marked out by nature for the first visible appearance in
the world of a new individual. Before fertilization, no
new individual exists. After it, sperm and egg cells are
gone-subsumed and transformed into a new, third entity capable
of its own internally self-directed development. By itself,
no sperm or egg has the potential to become an adult, but
zygotes by their very nature do.78
Many authors therefore regard the activation of the oocyte
(by the penetration of the sperm)79
or the completion of syngamy (the combining
of paternally- and maternally-contributed haploid pro-nuclei
to result in a unique diploid nucleus of a developing zygote)
as a meaningful marker of the beginning of a new human life
worthy of protection80
After this point, there is a new genome, in a new individual
organism, and there is a zygote (single-celled embryo) already
beginning its first cleavage and embarking on its continuous
developmental path toward birth.
All further stages and events in embryological development,
they argue, are discrete labels applied to an organism that
is persistently itself even as it continuously changes in
its dimensions, scope, degree of differentiation, and so
on. We can learn names for the various stages as if they
were static and discrete, but the living and developing
embryo is continuously dynamic.81
More to the point, in the view of these commentators no
discrete point in time or development would seem to give
any justification for assuming that the embryo in question
was one thing at one point and then suddenly became something
different (turning, for example, from non-human to human
or from non-person to person). None of the biological events
(or "points" in processes), they contend, is sufficient
to tell us what we are morally permitted or obligated to
do to human embryos, in the absence of one or another additional
premises that shape one's view of these biological events.
And if one's guiding premise is that all human persons possess
equal moral standing-regardless of their particular powers,
size, or appearance-then there are no grounds for denying
the earliest human embryo full moral standing as a person.
82
Some critics of this position argue that it makes too much
of mere genetic identity and (uncertain) potential or that
it does not make enough of present condition and the significance
of development itself.83
There is more to being human, some observers argue, than
possessing a human genome or spontaneous cell division,
and it matters that the early human embryo is but a ball
of cells, without sentience or sensation and without human
form.84
It matters, too, they argue, that an ex vivo human embryo
does not have the potential to develop independently, without
further technical intervention.85
Indeed, some argue that a human embryo in its earliest stages
is essentially no different from any human tissue culture
in the laboratory,86
or that, because the ex vivo embryo cannot develop if left
to itself, it cannot be thought of as truly continuous with
more developed human organisms. It may be, in the description
of one observer, not much different from a pile of building
materials stored in a warehouse.87
Nonetheless, advocates of the argument from continuity
suggest that it is dangerous to begin to assign moral worth
on the basis of the presence or absence of particular capacities
and features, and that instead we must recognize each member
of our species from his or her earliest days as a human
being deserving of dignified treatment. They contend that
a human embryo already has the biological potential needed
to enable the exercise, at a later stage of development,
of certain functions. Sentience and sensation come in later
in the process of development, but their seeds are there
right from the beginning. And the fact that an embryo cannot
develop outside the body is not an argument for leaving
it outside the body. There is, they argue, no clear place
to draw a line after the earliest formation of the organism,
and so there can be no stark division between the moral
standing of nascent human life and that of more mature individuals.88
2. The Case for Meaningful Discontinuity and Developing
Moral Status.
Many other observers, however, argue that some biologically
and morally significant discontinuities do in fact present
themselves in the course of early human development. These
arguments generally do not simply hinge on biological descriptions-which
are, in the absence of analysis, largely devoid of obvious
moral significance-but instead begin from some implicit
or explicit claim regarding the importance of a particular
feature, capacity, form, or function (or the progressive
accumulation of these) in defining a developing organism
as meaningfully a member of the human race.iv
Not simply grounded in biology, they appeal also to a moral
or even metaphysical claim about the meaning of humanity.89They
suggest that the developing human organism might become
(at once or progressively) deserving of protection as it
becomes able to feel pain, or to exhibit neural activity,
or rudimentary features of consciousness, or some elements
of the human form, or the capacity to function independently-or
as it progressively exhibits more and more of these or other
criteria. Until that time, many argue, a developing human
deserves some respect because of what it might become, but
not protection on par (or nearly so) with that afforded
to fully human subjects.90
They suggest that genetic identity and
organismic continuity are not sufficient; what matters is
present form and function, more than mere potential.91
Several particular putative discontinuities (and combinations
of them) have been proposed as candidates for the division
between early stages, when a human embryo may be disaggregated
for research, and later stages, when it deserves some greater
level of protection.
(a) Primitive streak: The most
popular candidate for a meaningful point of discontinuity
is the appearance of the primitive streak, the earliest
visible "structure" that defines the region of the embryo
along which the vertebral column will form. The primitive
streak generally appears around the 14 th day
after first cell division. It is taken to indicate the anterior-posterior
axis of an embryo (in vertebrates), although recent studies
suggest that polarity may be established much earlier, and
in fact may be indicated by the point at which the sperm
enters the egg. 92
A principal reason for the importance
placed on the primitive streak has to do with the biology
of twinning. Prior to the appearance of the primitive streak,
an embryo may (rarely, and for unknown reasons) divide completely
to form identical twins. Some conclude that individuality
must not yet be established, since the embryo might yet
become two embryos. 93
Since individuality is essential to human personhood and
capacity for moral status, since individuality presumes
a definitive single individual, and since the singularity
of the embryo is not irrevocably settled prior to the appearance
of the primitive streak, they argue that the entity prior
to the primitive streak stage lacks definitive individuality
and hence also moral status. 94
Critics of this line of reasoning point to the low statistical
probability of monozygotic twinning: one in 240 live births
(though rates clearly vary among populations in different
regions, and precise figures probably cannot be known because
some zygotes that split likely later fuse into one, and
some singleton births may conceal a twin who died early
in gestation). Critics also point to evidence that twinning
results, not from an intrinsic drive within the embryo,
but from a disruption of the fragile cell dynamics of embryogenesis.
Evidence for this, they suggest, may be seen in the increased
incidence of monozygotic twinning (up to ten fold in blastocyst
transfer) associated with IVF. This suggests, in their view,
that twinning is neither a proof of the absence of an integrated
individual organism with a drive in the direction of development
nor a demonstration ex post facto of the absence of moral
worth of the embryo before twinning. 95
Nonetheless, for this reason, and for
others (discussed below) having to do with the formation
of the nervous system, the primitive streak has often been
taken to be a highly significant marker of embryological
development, and many commentators suggest it as a reasonable
candidate for a meaningful point of discontinuity. For this
reason, many supporters of embryo research regularly propose
the 14 th day of development as a logical stopping
point for permissible embryo research. 96
(b) Nervous system: A second argument
for discontinuity focuses on the developing nervous system.
Many observers regard the nervous system as an especially
important marker of humanity, both because the human brain
is critical for all "higher" human activities, and because
the nervous system is the seat of sensation and, especially
relevant to this case, the sensation of pain. Proponents
of this view hold that before an embryo has developed the
capacity for feeling pain (or, in some forms of the argument,
before sentience), we cross no crucial moral boundary in
subjecting it to destructive research. 97
For some, this is taken to mean that the primitive streak,
as the first marker of a future nervous system, is a crucial
feature of developing life. For others, only later points
of neural development (where pain might plausibly be experienced)
are held to be decisive. 98
Critics meanwhile contend that neural development as well
as development of other systems (such as the cardio-vascular
system) are the natural outcome of the genetic program in
action, and should be explained by reference to the previous
stage and as leading to the subsequent stage, rather than
marking a significant discontinuity. 99
They maintain that the human being is, from the start, an
inseparable psycho-physical unity, rather than a pure rationality
or consciousness that exists with no meaningful ties to
our bodies. From a scientific perspective, such critics
hold, there is no meaningful moment when one can definitively
designate the biological origins of a human characteristic
such as consciousness, because our mind works in and through
our body, and the roots of consciousness lie deep in our
development. The earliest stages of human development serve
as the indispensable and enduring foundations for the powers
of freedom and self-awareness that reach their fullest expression
in the adult form. 100
Some of those who believe that neural development
is crucial, however, argue that the fact of non-sentience
and of an inability to experience pain possess great moral
significance, quite apart from the question of probable
potential.
(c) Human form: Some observers
also argue that certain rudimentary features of the human
form must be apparent before we can consider a human embryo
deserving of protection. In this view, the human form truly
signals the presence of a human life in the making and calls
upon our moral sentiments to treat the being in question
as "one of us." 101
Different versions of this argument appeal to different
particular elements (or combinations of elements) of the
human form as decisive, but all suggest that a "ball of
cells" is not recognizably human and therefore ought not
to be treated as simply one of us. 102
Some critics of this view argue that humans
have different external forms or shapes throughout their
lives, and that an organism, particularly in its early stages,
should not be judged by its external shape, but rather by
its biological constitution, and especially its genetic
identity. 103
But adherents of the argument that human form matters contend
that genetic identity cannot simply be decisive of moral
worth.
These various particular cases for discontinuity (and these
are not the only ones that have been propounded over the
years) are not mutually exclusive. Indeed, many of them
point to more than one particular element of early human
development as finally decisive of moral standing. But they
share the belief that moral status accrues only at some
later stage of the developing human organism. Their claim,
in the broadest terms, is that in its earliest stages a
human embryo is not yet simply a human being or a human
person, and that it need not be treated as though it were.104
Human development, they contend, is an
essential element in any understanding of human life, and
an organism at the earliest stages of that process is not
to be treated the same as one much farther along.105
There are developmental differences, and
these differences matter, in ways to be determined by human
choice and understanding, as well as by a grasp of the biological
facts.106
Critics of this view contend that while it is certainly
true that human beings at different stages of development
are not to be treated the same (as children are not given
the responsibilities of adults), the crucial treatment here
at issue is destructive treatment. No human being, at any
stage, they argue, should simply be destroyed for research,
and the "use" of an embryo for research, no matter how valuable
one deems the research to be, could not amount to treatment
of that embryo as "deserving some degree of respect." The
degree of respect granted in destroying the embryo would
be zero, they contend.107
Nonetheless, the case for developing moral status, as articulated
by a great number of participants in the policy debates
of the past several years, often results in an expression
of what has sometimes been termed the "special respect"
approach to human embryos: an embryo in its earliest stages
is not accorded the full moral standing of a human person,
but it is nonetheless regarded as deserving some degree
of respect and is treated as more than a mere object or
collection of somatic cells in tissue culture. In practice,
adherents of this view tend to accept the use of early human
embryos in medically valuable research under some circumstances,
but they seek to apply some scrutiny to the reasons for
which embryos will be used, the circumstances under which
those embryos are obtained, and other relevant factors.
Several bodies advising the federal government on human
embryo research over the years have expressed this view,
to varying degrees. The Ethics Advisory Board to the Department
of Health, Education and Welfare concluded in 1979 that
the early human embryo deserves "profound respect" as a
form of developing human life (though not necessarily "the
full legal and moral rights attributed to persons").108The
NIH Human Embryo Research Panel agreed in 1994 that "the
preimplantation human embryo warrants serious moral consideration
as a developing form of human life," though the panel argued
that this did not mean that research should be prohibited.109
In 1999, the National Bioethics Advisory Commission (NBAC)
cited broad agreement in society that "human embryos deserve
respect as a form of human life,"110
but, like its predecessors, did not recognize the embryo
as having the full rights of a human person. The special
respect position has been held by its advocates to be consistent
with a range of possible particular policies on embryo research,
including fairly restrictive ones, and indeed could be held
consistent even with an outright restriction on the destruction
of human embryos.v
111To
consider the embryo 'inviolable' (and therefore not a mere
utility to be instrumentally used), it is not necessary
to presuppose its moral equality with a child, an adult
or even a later stage gestating fetus. There may be increasing
moral obligations (and natural sentiments) associated with
a deepening relationality that extend moral duty without
in any way implicitly eroding an imperative of protection
at earlier stages of developing life. Most of those who
have articulated the special respect position in the public
debate have, however, tended to then argue that some research
on embryos should be permitted within certain boundaries,
even if they have not always agreed on the permissible extent
or the appropriate boundaries.
B. Special Cases and Exceptions
Some arguments in favor of permitting and funding embryo
research, grounded in the "special respect" approach, do
not in fact explicitly (or exclusively) rely on arguments
about discontinuity or a biologically grounded view of developing
moral status. Instead, or in addition, they rely upon questions
of embryo-viability and potential, and they are aimed at
exploring unique circumstances to address and perhaps resolve
questions of the moral standing of certain particular
human embryos.
1. IVF "Spares."
Much of the debate surrounding embryonic stem cell research
has focused on the use of cryogenically preserved IVF embryos,
left over from assisted reproduction procedures and stored,
perhaps indefinitely, in the freezers of IVF clinics. One
recent study suggests there are hundreds of thousands of
such embryos in the United States alone, though only a very
small percentage of them (less than 3 percent, approximately
3,000 or more) has ever been donated for research.112
Although all were produced with reproductive intent and
were stored for further reproductive efforts should the
first attempt fail, most of these frozen embryos may never
be claimed by the original egg and sperm donors for use
in assisted reproduction procedures. They are almost certain
to remain frozen and, eventually, to die without developing
further. Although there have been some efforts to build
interest in adopting such embryos, such adoption, some commentators
argue, is very unlikely to become a large-scale phenomenon
or to affect the fate of most of these stored embryos.113Under
the present funding policy, if these frozen embryos were
donated for research and embryonic stem cells were derived
from them, research on the resulting cells would not be
eligible for federal funding. Many observers argue that
it should be: Since these particular embryos are
almost certainly destined to die without ever developing,
it would be appropriate to at least redeem some possible
good from their existence and unavoidable demise.114
Some people have pushed the point further. Since the vast
majority of the (huge number of) cryopreserved embryos will
almost certainly not be adopted, and since many may not
be viable even if they were to be transferred to a woman's
uterus, a few observers have argued that, practically speaking,
the frozen embryos are virtually all already lost.115
To be sure, they are not already dead, but they are in a
so-called "terminal situation" from which no rescue is practically
possible. In view of this situation, one commentator proposes
extending to these embryos the principle that sometimes,
he argues, permits the killing of innocents. That is, killing
may be morally permissible in cases where the person will
soon die for other unavoidable reasons and where there is
another person who can somehow be rescued through or as
a result of such a normally impermissible act of killing
(thus, as he puts it, "nothing more is lost"). He admits
that the case of cryopreserved embryos stretches the application
of the "nothing is lost" principle beyond its previous uses,
because the embryos in question are alive and at risk of
death only because of human choices and designs specifically
directed toward them. The principle is also stretched because
the lives that might someday be saved through today's embryo
deaths are quite remote. The potential lives saved are those
of unspecified future persons with diseases that might be
treated by therapies that as yet do not exist and may or
may not exist in the future. However, against the weight
of all these ifs, which some find formidable, there
is the present fact that (like the embryos used to create
stem cell lines derived before August 9th of
2001) the cryopreserved embryos are already here, with little
or no prospect of rescue-they are, in this observer's description,
already lost.116
Presumably, if destruction of "spare embryos" for human
embryonic stem cell research were generally agreed to be
permissible through this "nothing is lost" principle, it
could be federally funded, subject to such routine secondary
considerations as the need for free and informed consent
by donors.
Yet this argument, not surprisingly, has met with opposition.
Some critics have claimed that it employs circular moral
reasoning. The embryos, they argue, are in a "terminal situation"
because of human choice and design; thus to then decide
that, since they are going to die anyway, they may as well
be put to good use is to ignore the moral implications of
the original decision to create and freeze them. Critics
argue, moreover, that when thinking about our responsibilities
to those who are soon to die, we would normally say that
it makes a considerable moral difference whether we simply
accept their dying or whether we positively embrace it as
our aim.117
Yet some proponents of using IVF spares argue that the present
situation is best understood as a forced choice between
two regrettable alternatives for the final disposition of
stored embryos (whether donated for research or abandoned).
One choice may then be justified as the lesser evil. Even
if one deems the original decisions leading to the creation
and storage of these embryos questionable, the embryos exist,
and the earlier decisions cannot be undone.118
Some have also worried about the possibility of a "slippery
slope," by which the uses of "spare" IVF embryos under this
justification might open the door to their wider use in
experiments in natural embryogenesis, toxicological studies
or chimerizations, or perhaps their development in an artificial
(or natural) endometrium,119
(though the reasonableness of "slippery slope" arguments
is often disputed).120
Other critics point out that the "nothing is lost" principle
is not permitted to govern decisions regarding lethal experiments
on the terminally ill, on death-row inmates, or even on
fetuses slated for abortion.121
A further issue involves the question of whether accepting
the "nothing is lost" principle for already existing
embryos condones in principle the use of future excess embryos,
or whether the principle actually requires efforts to prevent
the creation or storage of "excess" embryos in the future.122
Further, this application of the principle
relates only to embryos originally created for the purpose
of reproduction but not transferred to initiate a pregnancy.
Should their use in research be accepted, however, it is
not clear that it would be possible to differentiate between
embryos created originally for reproduction and extra embryos
created with an eye to research uses, since the process
of producing them would be identical (though consideration
of the extra risks involved for the woman egg donor could
act as a counter against any large-scale embryo-creation-for-research).123
Other observers, however, begin from the presence of cryogenically
preserved embryos but extend further the argument justifying
their use in research. They argue that there is good reason
to use embryos for research, not only because a situation
some judge tragic already exists but because donating embryos
is an act of beneficence and using them is a social obligation
incurred by their gift.124This
approach would have us start by recognizing that, in the
current situation, there is a set of embryos (in IVF clinics)
none of which will ever enter a uterus, or even a (still
hypothetical) artificial uterus.125
These embryos, in one commentator's term, are "unenabled"
and have no potential for full development. Since there
is no possible way for such embryos to develop, there is
no "possible person" to whom any "unenabled" embryo corresponds;
therefore using them in research involves no loss of possible
life.126
Critics of this approach argue that in effect it allows
the moral standing of any given embryo to be decided simply
by those responsible for it. Thus, whether a given embryo
has moral standing depends only on whether it has a practical
prospect of developing, as evidenced by whether it will
be transferred to a uterus. But whether it enters a uterus
depends on human choices, so the moral standing of a given
embryo depends on human choices. If we choose to withhold
essential enabling conditions for an embryo's development,
these critics argue, then that embryo will lack not moral
standing but merely the opportunity to develop. Its intrinsic
nature, including its own potential to develop (given
needed conditions), has not changed.127
Nonetheless, in the view of a number of commentators, the
fact that so many frozen embryos already exist (even if
only a small percentage of them are donated for research)
changes the balance of duties and respect owed to any single
ex vivo embryo. Several observers have argued that the presence
of these frozen embryos, with little or no chance of attaining
birth, creates special circumstances in which the use of
embryos in research (whether destroying them in the course
of research or allowing them to die and subsequently using
them)128
is independent of any final judgment regarding the moral
standing or worth of the ordinary human embryo, as such.129
2. Natural Embryo Loss.
Some authors tie their moral arguments regarding the use
of embryos in research to the fact of the high rate of embryo
loss under natural conditions of sexual intercourse and
unassisted reproduction. They argue that directed destruction
of ex vivo embryos for the purpose of research would not
result in greater embryonic loss than occurs in this natural
process and would result in far greater benefits for humanity.130
The rate of natural embryo loss after conception in unassisted
human reproduction (taking in losses both before and after
implantation), though not accurately known, is thought to
be high, some suggest as high as 80 percent.131
Moreover, the fact of natural loss is now fairly well known,
so that persons who engage in unprotected intercourse, whether
seeking to reproduce or not, are knowingly bringing about
the conception of many embryos that will die. We generally
do not regard this embryo loss as unacceptably tragic, and
we do not engage in great efforts to avert it or to find
ways to diminish it (beyond research to prevent miscarriage,
or instance). For this reason, these commentators argue,
using artificially created embryos for purposes of research
would not destroy a greater portion of those embryos than
ordinarily die in natural unassisted reproduction.132
Moreover, they suggest, the high rate of natural embryo
loss should call into question the views of those who believe
that early-stage human embryos merit equal treatment with
human children and adults. If so many die in the natural
course of things, why do we not treat natural procreation
as a great fountain of tragedy and carnage? The natural
rate of embryo loss, and most people's failure to mourn
its consequences, they suggest, should teach us something
about the limited significance of human embryos in the earliest
stages. One observer adds that the same logic should diminish
our concerns about creating extra human embryos for research,
as long as sufficient embryos are created for implantation
to keep the chances of survival for any given embryo as
good as the chances in natural reproduction.133
Another argues further that human embryonic stem cell research
might actually raise the probability of longer survival
for all humans, including embryonic ones, and is therefore
a case of permissible taking of life, even on the assumption
that the embryos are persons.134
Opponents of this view, however, have argued that natural
deaths of embryos and the deaths caused by intentional efforts
to destroy ex vivo embryos for research are not morally
equivalent. There are many things that happen naturally
that we are not therefore justified in doing deliberately.
Indeed, the rate of natural loss of live-born human beings
is 100 percent, but that does not justify their killing.
And, they argue, even if one were permitted to analogize
the deaths of frozen embryos in vitro to the embryonic wastage
in vivo, in neither case were the embryos lost destined
or created for anything other than their procreative end.
In contrast, they argue, using embryos for research bears
no relation to their natural direction or trajectory. Critics
also argue that the character of our reaction to the natural
embryonic death does not justify our practice of destructive
embryo research. For they believe that a creature's moral
worth is not dependent on the emotional reaction of others
to its death.135The
absence of moral sentiment does not imply an absence of
moral obligation (nor a right of adverse intervention in
a naturally developing human life). Moreover, critics contend,
it is not clear how many of these "natural losses" were
in fact failures of the fertilization process, so that there
was never a unified, integrated organism in the first place,
and thus never the loss of a human embryo. It is also unclear,
they argue, how much of the supposedly "natural" loss rate
is actually due to contingent and changeable factors such
as environmental pollution, pesticides, or endometrial problems,
and so is not simply an unavoidable fact of embryonic existence.136
3. Prediction of Non-Viability of Embryos.
Some people, hoping to get around the moral dilemma of
destroying even "unenabled" embryos, seek to identify a
subset of embryos that might reasonably be regarded in advance
as non-viable. One proposal has involved the possibility
that cloned human embryos, created by somatic cell nuclear
transfer, may prove to be non-viable or unable to develop
beyond a certain point (biological evidence that this may
be the case is presented by Rudolph Jaenisch in appendix
N) or may even, by their nature and origins, simply not
constitute the equivalent of human embryos. If this turns
out to be true, it is further argued, it might be possible
to use them without arousing some of the ethical dilemmas
that accompany the use of otherwise potentially viable human
embryos.137
Others point to a possible sub-group of those embryos currently
frozen in storage as potentially non-viable. Although those
embryos are not yet dead and, if thawed, would still exhibit
some cellular function, some would be unlikely to survive
even were transfer attempted. Since IVF procedures usually
produce more embryos than can be transferred at one time,
goes the argument, the clinicians choose for transfer those
among the available embryos that look "the best" and seem
most likely to survive and develop-so that those that are
frozen are those deemed less likely to develop. Moreover,
by applying similar judgment to the unimplanted embryos,
we might identify those that would be least likely to survive
even under the most favorable circumstances. These embryos
might then reasonably be regarded as non-viable and therefore
available for research since their use will not disrupt
a potential life.138
There has not been much direct reaction to this view in
the ongoing ethical debates. Yet some observers have noted,
in other contexts, that the techniques used to identify
which IVF embryos are more or less likely to develop successfully-estimates
based usually on visual assessment of the embryos-have never
been proven effective or even tested to ascertain their
validity.139
Moreover, some argue, the true viability of cloned human
embryos or of cryogenically stored embryos could not be
determined in advance without attempting to implant them.140
4. Creation of Non-Viable Embryo-Like Artifacts.
Others, seeking to by-pass altogether the issue of viability,
propose the possibility of creating a biological entity
that cannot rightly be called a living organism, yet that
has the generic organic powers necessary to produce embryonic
stem cells. They suggest that somatic cell nuclear transfer,
or a similar technique, could be used to create an entity
that lacks, by design, the qualities and capabilities essential
to be designated a human life in process. By intentional
alteration of the somatic cell nuclear components or the
cytoplasm of the oocyte into which they are transferred,
researchers may be able to construct an "artifact" that
is biologically (and morally) more akin to cells in tissue
culture, but could still provide a source of functional
human embryonic stem cells.141
Proponents of this innovation aim to shift the ethical debate
from the question of whether or when a human embryo should
be considered a human being to the question of which organized
structures and potentials constitute the minimal criteria
for considering an entity to be a human embryo.142
Absent all the essential elements (including a full complement
of chromosomes, proper genetic sequence and chromatin configuration,
and cytoplasmic structures and transcription factors), advocates
of this proposal argue, there can be no integrated whole,
no organism, and hence no human embryo. By technically constructing
biological entities lacking these essential elements yet
bearing the partial organic potential often found in failures
of fertilization, they suggest it may be possible to procure
embryonic stem cells without producing an organismal or
embryonic entity that can meaningfully be designated a being
with moral standing.143
Proponents argue that there is a natural biological precedent
for such an entity lacking the qualities and characteristics
of an organism yet capable of generating cells with the
character of embryonic stem cells. Teratomas are germ cell
tumors that generate all three germ layers as well as more
advanced cells, tissues, and partial limb and organ primordia.
Yet these chaotic, disorganized, and nonfunctional masses
lack entirely the structure and dynamic character of an
organism. Likewise, failures of fertilization due to abnormal
complements or chromatin configurations (imprinting) of
the chromosomes may still proceed along partial trajectories
of organic growth without being meaningfully designated
as organismal entities.
These natural examples of "partial generative potential"
(described by some as 'pseudo-embryos), together with other
observations of early embryonic process, have led to a diverse
array of suggestions for ways that embryonic stem cells
may be produced without raising the moral issues involved
in the creation and destruction of human embryos. These
suggestions include the use of aneuploidies, polyploidies,
viable cells from embryos in arrested development, parthenotes,
and chimeras of human nuclear material and animal oocytes.
Each presents its own particular technical challenges and
raises unique and unfamiliar moral considerations. The scientific
prospects for such projects remain largely unexplored in
humans, though some animal work has shown promise, and proponents
argue that they are within the reach of current technology.144
The crucial principle in all such efforts, proponents argue,
is the preemptive nature of the intervention: undertaken
at a stage before the transition to organismal status. They
contend that just as we have learned that neither genes,
nor cells, nor even whole organs define the locus of human
moral standing, in this era of developmental biology we
will come to recognize that cells and tissues with "partial
generative potential" may be used for medical benefit without
a violation of human life or dignity. Moreover, they argue,
the moral distinctions essential to discern and define the
categories of organism, embryo, and human being will be
critical to progress in scientific research involving embryonic
stem cells, chimeras, and laboratory studies of fertilization
and early embryogenesis. These advances in developmental
biology, they contend, will depend on clarifying these categories
and defining the moral boundaries in a way that at once
defends human dignity while clearing the path for scientific
progress.145
This proposal has drawn criticism on several fronts. First,
critics suggest, it would require significant research to
assure that the procedure reliably produced the desired
sort of "non-embryonic" entity yet also still yielded normal
human embryonic stem cells, and such research might itself
be morally problematic. Second, this proposal raises a series
of further scientific and ethical questions, including those
regarding the minimal degree of "partial generative potential"
for an entity to be considered an organism, and for an entity
to be considered a human embryo. They point further to the
risk of creating entities that are so ambiguous as to leave
their moral standing in serious doubt, at least for those
people who believe that the early stages of human life have
at least some moral worth. Finally, proposals to use human
oocytes raise moral concern regarding the source of supply,
in this case as in the larger arena of in vitro fertilization
and experimentation.146
Although this approach has never been tested in humans,
animal experiments suggest it has potential, and it has
begun to play a part in the debates over the moral standing
of human embryos and the permissibility of embryo research
more generally.
V. Societal Significance and Public
Responsibility
While the bulk of the public debate surrounding embryonic
stem cell research has been directed to the question of
the moral standing of human embryos, some commentators have
raised a number of other crucial and serious concerns. They
have argued that the debate suffers from focusing too narrowly
on questions of the standing of human embryos, when other
issues-including the duties and responsibilities of those
who engage in embryonic stem cell research, the implications
of such uses of nascent life for our society (rather than
just for the embryos themselves), the significance of the
public debate, and a series of other issues-also bear heavily
on the subject, and may illuminate it in ways at least as
significant.147
Some authors, including some who do not believe
that human embryos should simply be treated as inviolable
persons, have argued that the instrumentalization of human
embryos-the seeds of the next generation-might tend to coarsen
the sensibilities of our society toward future generations,
and toward human life in general, quite apart from the effects
on the embryos themselves.148
Others also argue that by setting down the path laid out
by human embryonic stem cell research, we open the way for
other, and more troubling, techniques and developments.
Since human suffering and disease will never come to an
end, they suggest, the resort to extreme and potentially
exploitative methods is unlikely to find a logical stopping
point. Today, they argue, scientists want to use only the
earliest embryos; but what will happen when it turns out
that later-stage embryos are even more valuable in developing
treatments for disease?149
Critics of this view have generally argued that it fails
to offer a sufficient ground for impeding the promise and
potential of medical treatments that might result from embryonic
stem cell work. These critics see medical research as a
central moral duty, and they argue that a society that prevents
such research undermines not only medical progress, but
the moral progress of the community as a whole. While instrumentalization
and moral coarsening are real worries, these critics argue,
long-term fears of a "slippery slope" do not justify renouncing
the potential of today's research. Future difficulties,
they say, can be faced if and when they arrive in earnest.150
Other observers have raised concerns related to the ethical
and policy debate itself, rather than to the specifics of
one technique or another, or of one funding policy or another.
Some, for instance, have argued that what is needed in the
human embryonic stem cell research debate is not only an
exchange of views about the substantive issues (though that
is surely crucial) but also some sense of the appropriate
democratic process for deliberation and for establishing
appropriate public policy on such a profoundly contentious
matter. The embryonic stem cell debate, it is argued, offers
a valuable opportunity to think through the ways in which
the American polity debates the most contentious moral issues.151
Some even suggest that such matters should be removed from
the political process altogether, and left in the hands
of a regulatory body specifically charged with monitoring
and decision-making authority.152
Other observers worry that the promise of embryonic stem
cell research to bring swift or immediate cures to those
who are now ailing has been oversold. They point out that,
two decades ago, similar claims of rapid cures were made
on behalf of fetal tissue transplantation research, but
have not as yet been realized (though, of course, the danger
of unfulfilled hope always looms over medical research).
Such talk, some observers have argued, tends to raise false
hopes, and thus does a genuine disservice to the sick and
disabled.153
Worse, some regard it as cruel and immoral to exploit the
hopes and fears of the desperately ill and their families,
especially when-as several scientists in the field have
remarked-it is not very likely that stem cell based remedies
will be available for most people now suffering from the
potentially targeted diseases. This moral concern is tied
directly to the longstanding bioethical principle of truth-telling,
which obliges physicians to inform their patients honestly
about their condition and prognosis and encourages researchers
to be truthful in their assessments of the potential for
new treatments and cures, whether or not what they have
to say is what patients and their loved ones want to hear.
"It is misleading to suggest that stem cells will bring
cures," one writer observes, "particularly cures for patients
now coping with the serious diseases the research targets."154
A related concern, raised by some of the same commentators,
involves what has been termed "the disproportionate emphasis
on stem cell research in contemporary health politics."155The
prominence of this debate in American politics, they argue,
may tend to distract us from the fact that many Americans,
and even more people elsewhere, lack very basic healthcare
and have no access to those medical tools and techniques
that already exist and that raise no profound controversy.156
The concern for justice, and for the proper
setting of priorities, they argue, requires us to see this
line of research in its proper perspective. Because federal
resources for research are limited, decisions must be made
about which areas should receive high (and low) priority,
and decisions must be made about how much to devote to research
and how much to devote to programs that provide proven health
care to patients. These commentators suggest that this view
does not mean that stem cell research should not be funded,
but only that we must keep in mind that funds are also needed
for many other approaches to fighting suffering and disease.157
Critics of this view, however, respond that an excessive
preoccupation with existing health care needs can
jeopardize new medical research and medical progress, and
that today's "basic medicine" was once experimental research.158
Meanwhile, others have argued that the debate has been
too narrow in another way. Any federal policy, they suggest,
must take note not only of the potential promise of embryonic
stem cell science, but also possible alternatives to such
research, alternatives less morally troubling to many Americans.
Many opponents of public funding for human embryonic stem
cell research, for instance, have argued that more attention
should be paid, and more resources devoted, to adult
stem cell research, which raises few of the moral difficulties
present in the embryonic stem cell debates159
(though, for some, it still does raise a number of ethical
difficulties).160Such
work, they contend, might even make embryonic stem cell
research (or, at the very least, publicly funded embryonic
stem cell research)161
unnecessary, if it proves sufficiently useful.vi
In response, however, others point out that adult stem
cell research already receives about ten times the amount
of federal funding apportioned to human embryonic stem cell
research. Critics also argue that embryonic stem cells may
possess unique advantages over adult stem cells, just as
(in some circumstances) the opposite may be the case, and
that therefore both avenues, as well as research using stem
cells derived from fetal tissue, should be pursued simultaneously.162
And they contend that opponents of embryonic stem cell research
have oversold the promise of adult stem cells so that the
public might come to see embryonic stem cell research as
unnecessary.163
In the next chapter, we examine some of the scientific facts
regarding adult and embryonic stem cells, but in the context
of the ethical and political debates, the distinctions between
them have been quite important and prominent.
In these ways, the controversial possibility of scientific
alternatives, as well as concerns about the health of American
culture and democracy, the honesty of a political debate
that touches on the hopes and fears of many who are suffering,
and the bigger picture of health-care politics all impinge
upon the question of federal funding of human embryonic
stem cell research.
VI. Conclusion
Participants in the public debate surrounding human embryonic
stem cell research and the administration's funding policy
have addressed themselves to many complicated and difficult
ethical matters: the character of the moral question at
issue; the nature, object, ethical assumptions, and premises
of the policy itself; the vexing question of what is owed
to the early human embryo; and a number of other related
concerns. As we have seen, strong and powerfully argued
views have been presented on various sides of each of these
questions. For now, neither side to the debate seems close
to fully persuading the other of the truth it thinks it
sees. But the rich and growing ethical debates do suggest
the possibility of progress toward greater understanding
of the issues, and toward more informed public decision-making,
as all parties to the deliberation appreciate better just
what is at stake, not only for them or their opponents,
but indeed for all of us.
_________________
Footnotes
i. Only "the now,"
created by an act of speaking, defines the difference
between past and future (tenses and deeds).
ii. Lori Andrews
detailed both these ongoing efforts and existing legislation
in the states in her presentation at the Council's July
2003 meeting and in the accompanying paper. (See Appendix
E.)
iii. Readers may
find it helpful to consult the notes on Early Human Development
(Appendix A).
iv. Also, several
traditional religious views of the embryo (among some
Jews and some Muslims, for instance) have attributed humanity
to the embryo only after a particular point in its development,
for example the 40th day.
v. This is partly
due to the fact that "special respect," and "intermediate
moral status," are rather vague terms, and embrace a very
wide range of degrees of "specialness" and "intermediacy."
vi. In 1999,
the National Bioethics Advisory Commission stated that
"In our judgment, the derivation of stem cells from embryos
remaining following infertility treatments is justifiable
only if no less morally problematic alternatives are available
for advancing the research," though the commission did
not conclude that adult stem cells were sufficiently
shown to offer such an alternative. (National Bioethics
Advisory Commission, Ethical Issues in Human Stem cell
research, Washington, D.C.: Government Printing Office,
1999, p. 53.)
_________________
ENDNOTES
1.
"Press Conference by President Bush and Italian Prime Minister
Berlusconi," as made available by the White House Press
Office, July 23, 2001.
2.
See, for instance, Weissman, I. L., "Stem Cells-Scientific,
Medical and Political Issues," New England Journal of
Medicine 346(20): 1576-1579 (2002).
3.
See, for instance, Green, R., "Determining Moral Status,"
American Journal of Bioethics 2(1): 28-29 (2002).
4.
See, for instance, Orr, R., "The Moral Status of the Embryonal
Stem Cell: Inherent or Imputed?" American Journal of
Bioethics 2(1): 57-59 (2002).
5.
See, for instance, Doerflinger, R., "Ditching Religion and
Reality," American Journal of Bioethics 2(1): 31
(2002).
6.
See, for instance, Latham, S., "Ethics and Politics," American
Journal of Bioethics 2(1): 46 (2002).
7.
See, for instance, Marquis, D., "Stem cell research: The
Failure of Bioethics," Free Inquiry 22(1): Winter
2002.
8.
See, for instance, the presentation of Richard Doerflinger
before the Council on June 12, 2003. A transcript of that
presentation is available on the Council website at www.bioethics.gov.
9.
See, for instance, FitzGerald, K., "Questions Concerning
the Current Stem Cell Debate," American Journal of Bioethics
2(1): 50-51 (2002).
10.
See, for instance, Haseltine, W., "Regenerative Medicine:
A Future Healing Art," Brookings Review, Winter 2003.
11.
See, for instance, Stolberg, S., "Scientists Urge Bigger
Supply of Stem Cells," The New York Times, September
11, 2001, p. A1.
12.
See, for instance, Perry, D., "Patients' Voices: The Powerful
Sound in the Stem Cell Debate," Science 287: 5457,
1423; and the presentation of Irving Weissman before the
Council on February 13, 2002, available on the Council website
at www.bioethics.gov.
13.
This point was taken up by the Council in its report Human
Cloning and Human Dignity: An Ethical Inquiry (July
2002), Chapter 6, pp. 167-168.
14.
One useful description of this approach to the issue is
Zoloth, L., "Jordan's Banks, A View from the First Years
of Human Embryonic Stem Cell Research," American Journal
of Bioethics 2(1): 7 (2002).
15.
Callahan, D., What Price Better Health: The Hazards of
the Research Imperative. Los Angeles, CA.: University
of California Press, 2003; also see Daniel Callahan's presentation
before the Council on July 24, 2003, available on the Council's
website at www.bioethics.gov.
16.
FitzGerald, K., op. cit., pp. 50-51.
17.
For examples, see Weiss, R., "Legal Barriers to Human Cloning
May Not Hold Up," The Washington Post, May 23, 2001.
18.
See, for instance, Elias, P., "States, Feds May Clash over
Cloning Rules," Genomics and Genetics Weekly, April
12, 2002, p. 24.
19.
This, for instance, was the line of reasoning of the American
Bar Association when, in August of 2002, it issued a resolution
supporting limited therapeutic research using cloned human
embryos. The report of the ABA's Section of Individual Rights
and Responsibilities (available from the ABA) lays out the
case.
20.
See, for instance, Russo, E., "Policy Questions and Some
Answers," The Scientist, April 15, 2003.
21.
R. Alta Charo, of the University of Wisconsin Law School,
quoted in Coyle, M., "The Clone Zone," The National Law
Journal, May 15, 2002.
22.
Alan Meisel of the University of Pittsburgh School of Law,
quoted in Coyle, M., "The Clone Zone," The National Law
Journal, May 15, 2002.
23.
Berkowitz, P., "The Meaning of Federal Funding," a paper
commissioned by the President's Council on Bioethics and
included as Appendix F of this report.
24.
See: Maher v. Roe 432 U.S. 464 (1977); Harris
v. McRae 448 U.S. 297 (1980); Rust v. Sullivan
500 U.S. 173 (1991).
25.
Berkowitz, P., "The Meaning of Federal Funding," a paper
commissioned by the President's Council on Bioethics, and
included as Appendix F of this report. See also Khushf,
G., and Best, R., "Stem Cells and the Man on the Moon: Should
We Go There from Here?" American Journal of Bioethics
2(1): 38 (2002).
26.
FitzGerald, K., op. cit., pp. 50-51.
27.
Doerflinger, R., op. cit., p. 31.
28.
Childress, J., "Federal Policy Toward Embryonic Stem cell
research," American Journal of Bioethics 2(1): 34
(2002).
29.
Kahn, J., "Missing the mark on stem cells," Bioethics
Examiner 5:3, Fall 2001, p. 1.
30.
Murray, T., "Hard Cell," The American Prospect, September
24, 2001.
31.
See, for instance, Lefkowitz, J., "The Facts on Stem Cells,"
The Washington Post, October 30, 2003, p. A23; and
Bush, G.W., "Stem Cell Science and the Preservation of Life,"
The New York Times, August 12, 2001, p. D13.
32.
"How many lines," The Washington Post, August
31, 2001, p. A22.
33.
Daley, G., "Cloning and Stem Cells-Handicapping the Political
and Scientific Debates," New England Journal of Medicine
349(3): 211-212 (2003).
34.
Kennedy, D., "Stem Cells: Still Here, Still Waiting," Science
300: 865 (2003).
35.
See, for instance, Brickley, P., "Scientists Seek Passports
to Freer Environments," The Scientist 15:36 (2001).
36.
See, for instance, Weissman, I., "Stem Cells-Scientific,
Medical and Political Issues," New England Journal of
Medicine 346(20): 1578-1579 (2002).
37.
See, for instance, Weise, E., "USA's Stem Cell Scientists
Fear a Research Brain-Drain," USA Today, May 12,
2003, p. 6D.
38.
Clark, J., "Squandering Our Technological Future," The
New York Times, August 30, 2001, p. A19. See also the
presentation of Thomas Okarma, President and CEO of Geron
Corporation, before the Council on September 4, 2003. The
full transcript of Okarma's presentation may be found on
the Council's website at www.bioethics.gov.
39.
Robertson, J., "Crossing the Ethical Chasm: Embryo Status
and Moral Complicity," American Journal of Bioethics
2(1): 33 (2002).
40.
See, for instance, Pizzo, P., "Remove Obstacles to Stem
cell research," San Jose Mercury-News, June 19, 2003;
and Holden, C. and Vogel, G., "'Show Us the Cells' U.S.
Researchers Say," Science 297: 923 (2002).
41.
The most notable discussion of safety concerns has been
Dawson, L., et al., "Safety Issues in Cell-Based Intervention
Trials" Fertility and Sterility 80: 5, 1077-1085,
2003. We must note, however, that the assessment of the
subject presented in that article relies upon the assumption
that "all of [the approved] lines were derived using mouse
feeder layers." (p. 1078). In his presentation before the
Council on September 4, 2003, NIH Director Elias Zerhouni
flatly contradicted this assertion, telling the Council
that "there are at least those, which is about 16 lines,
I believe, that have not been exposed to either mouse or
human cell-human feeder cell lines." (The transcript of
Zerhouni's presentation is available on the Council's website
at www.bioethics.gov.) Those eligible unexposed lines,
however, are not presently among the lines available
to researchers, and it cannot be known in advance if or
when they might become available or whether they will prove
useable. In addition, the FDA has stated that even in the
case of those lines that were developed with mouse feeders,
"FDA does not intend that the agency's regulation of xenotransplantation
will preclude the use of these hES cell lines." (Food and
Drug Administration, "Guidance for Industry - Source Animal,
Product, Preclinical, and Clinical Issues Concerning Use
of Xenotransplantation Products in Humans," April 3, 2003.)
FDA Commissioner Mark McClellan also made that clear in
his presentation before the Council, available at the Council's
website.
42.
Faden, et al., "Public Stem Cell Banks: Considerations of
Justice in Stem Cell Research and Therapy" Hastings Center
Report 33:6 (2003).
43.
See, for instance, Capron, A., "Stem Cell Politics: The
New Shape to the Road Ahead," American Journal of Bioethics
2(1): 35-36 (2002).
44.
Robertson, J., op. cit., pp. 33-34.
45.
See, for instance, the testimony of HHS Secretary Tommy
Thompson before the Senate Health, Education, Labor and
Pensions Committee, September 5, 2001; and Lefkowitz, J.,
"The Facts on Stem Cells," The Washington Post, October
30, 2003, p. A23.
46.
Brownstein, R., "Bush Won't Budge on Stem Cell Position,
Health Secretary Says," Los Angeles Times, August
13, 2001, p. A9.
47.
This comment was made by Council Member Gilbert Meilaender
in Council discussion on September 4, 2003. A transcript
of that discussion is available on the Council's website
at www.bioethics.gov.
48.
See, for instance, FitzGerald, K., op. cit., pp.
50-51.
49.
Khushf, G., and Best, R., op. cit., p. 38.
50.
See, for instance, the discussion of the Council in its
September 4, 2003 meeting, particularly the argument elucidated
by Council Member Michael Sandel. A transcript of that session
is available on the Council website at www.bioethics.gov.
51.
See, for instance, Stolberg, S., op. cit.
52.
See, for instance, Robertson, J., "Ethics and Policy in
Embryonic Stem cell research," Kennedy Institute of Ethics
Journal 9(2): 109-136 (1999); Spike, J. "Bush and Stem
cell research: An Ethically Confused Policy," American
Journal of Bioethics 2(1): 46 (2003); and Capron, A.,
op. cit., p. 36.
53.
The statement was made by bioethicist Glen McGee, in reference
to the Clinton-era proposed NIH rules on funding, quoted
in Spanogle, J., "Transforming Life," The Baylor Line,
Winter 2000, p. 30.
54.
The remark was made by Bishop Joseph A. Fiorenza, President
of the U.S. Conference of Catholic Bishops, in a news release
("Catholic Bishops Criticize Bush Policy on Embryo Research,"
made available by the United States Conference of Catholic
Bishops, August 9, 2001).
55.
This argument arose in the course of Council discussion
on September 4, 2003 (see particularly the comments of Council
Members Michael Sandel and Charles Krauthammer in that discussion).
A transcript of that session is available on the Council's
website at www.bioethics.gov.
56.
Ibid., see particularly the comments of Council Members
Mary Ann Glendon and Gilbert Meilaender in that discussion.
57.
For these guidelines, see Appendix D.
58.
Ibid., see particularly the comments of Council Member
William Hurlbut in that discussion.
59.
Some reasons to regard public funding of activities in a
light different from mere permission are proposed in Khushf,
G., and Best, R., op. cit., p. 38.
60.
"Remarks by the President on Stem-cell research," as made
available by the White House Press Office, August 9, 2001.
61.
"President's Phone Call to March for Life Participants,"
as made available by the White House Press Office, January
22, 2002.
62.
See Council discussion on September 4, 2003, especially
comments by Council Members Charles Krauthammer, Francis
Fukuyama, Gilbert Meilaender, and Leon Kass. A transcript
of that session is available on the Council's website at
www.bioethics.gov.
63.
Bush, G.W., "Stem Cell Science and the Preservation of Life,"
The New York Times, August 12, 2001, p. D13.
64.
"Remarks by President George W. Bush on Stem Cell Research,"
as made available by the White House Press Office, August
9, 2001.
65.
See, for instance, Council discussion on September 4, 2003
(particularly the comments of Council member Michael Sandel
and invited guest Peter Berkowitz in that discussion). A
transcript of that session is available on the Council's
website at www.bioethics.gov.
66.
"Remarks by President George W. Bush on Stem Cell Research,"
as made available by the White House Press Office, August
9, 2001.
67.
See, for instance, Council discussion on September 4, 2003
(particularly the comments of Council Members Charles Krauthammer
and James Wilson in that discussion). A transcript of that
session is available on the Council's website at www.bioethics.gov.
68.
For instance, in discussing research on cloned human embryos,
President Bush said, "Research cloning would contradict
the most fundamental principle of medical ethics, that no
human life should be exploited or extinguished for the benefit
of another. Yet a law permitting research cloning, while
forbidding the birth of a cloned child, would require the
destruction of nascent human life." ("Remarks by the President
on Human Cloning Legislation," as made available by the
White House Press Office, April 10, 2002); and in explaining
his stem cell funding policy, the President wrote: "While
it is unethical to end life in medical research, it is ethical
to benefit from research where life and death decisions
have already been made." (Bush, G.W., "Stem Cell Science
and the Preservation of Life," The New York Times,
August 12, 2001, p. D13.)
69.
As noted previously, in August of 2001 Health and Human
Services Secretary Tommy Thompson told reporters that "neither
unexpected scientific breakthroughs nor unanticipated research
problems would cause Bush to reconsider." (See, Brownstein,
R., "Bush Won't Budge on Stem Cell Position, Health Secretary
Says," Los Angeles Times, August 13, 2001, p. A9).
70.
One useful account of these issues is Cohen, E., "Of Embryos
and Empire," The New Atlantis 2: 3-16 (2003).
71.
See, for instance, London, A., "Embryos, Stem Cells, and
the 'Strategic' Element of Public Moral Reasoning," American
Journal of Bioethics 2(1): 56 (2002).
72.
For examples of this way of proceeding-both in arguments
supporting embryo research, and arguments opposing it-see,
among numerous other sources, the Council's July 2002 report,
Human Cloning and Human Dignity: An Ethical Inquiry,
Chapter 6.
73.
See, for instance, McCartney, J., "Embryonic Stem cell research
and Respect for Human Life: Philosophical and Legal Reflections,"
Albany Law Review 65: 597-624 (2002).
74.
See, for instance, Orr, R., op. cit., pp. 57-58.
75.
See, for instance, Steinberg, D., "Can Moral Worthiness
Be Seen Using a Microscope?" American Journal of Bioethics
2(1): 49 (2002).
76.
See, for instance, Green, R., op. cit., p. 20.
77.
See, for instance, Doerflinger, R., op. cit., pp.
31-33; Orr, R., op. cit., pp. 57-58; and the personal
statements of Council Members William Hurlbut and Robert
George and Alfonso Gómez-Lobo, in the Council's July 2002
report Human Cloning and Human Dignity: An Ethical Inquiry,
among others.
78.
See, for instance, Orr, R., op. cit., pp. 57-58.
79.
See, for instance, the personal statement of Council Member
William Hurlbut, in the Council's July 2002 report Human
Cloning and Human Dignity: An Ethical Inquiry.
80.See,
for instance, Sullivan, D., "The Conception View of Personhood:
A Review," Ethics and Medicine 19(1): 11-33 (Spring
2003).
81.
A form of this argument was presented by some Members of
the Council in the Council's July, 2002 report Human
Cloning and Human Dignity: An Ethical Inquiry, chapter
6, and in several of the personal statements appended to
that report.
82.
See, for instance, Steinberg, D., op. cit., p. 49.
83.
See, for instance, the transcript of Council discussion
on October 17, 2003, especially the comments of Council
Member Elizabeth Blackburn. The full transcript is available
on the Council's website at www.bioethics.gov. Also see
Green, R., op. cit., pp. 20-30.
84.
See, for instance, Lanza, R., et al., "The Ethical Validity
of Using Nuclear Transfer in Human Transplantation," Journal
of the American Medical Association, 284(24): 3175-3179
(2000). Also, see the views expressed by some Members of
this Council in our July 2002 report Human Cloning and
Human Dignity: An Ethical Inquiry, chapter 6, and in
the personal statements of Council Members Elizabeth Blackburn,
Michael Gazzaniga, and Janet Rowley.
85.
See, for instance, the transcript of Council discussion
on April 25, 2002, especially the comments of Council Member
Daniel Foster. The full transcript is available on the Council's
website at www.bioethics.gov.
86.
See, for instance, the position articulated in "Position
Number Two" of the "Moral Case for Cloning for Biomedical
Research" presented by some Members of the Council in the
Council's July, 2002 report Human Cloning and Human Dignity:
An Ethical Inquiry, Chapter 6; and the personal statement
of Council Member Michael Gazzaniga, appended to that report.
87.
See, for instance, the comments of Council Member Michael
Gazzaniga (and response from other Members) during Council
discussion on February 14, 2002. The full transcript is
available on the Council's website at www.bioethics.gov.
88.
See, for instance, Orr, R., op. cit., pp. 57-59;
Callahan, S., "Zygotes and Blastocysts: Human enough to
protect," Commonweal, June 14, 2002; the position
articulated by several Members of this Council in our July
2002 report Human Cloning and Human Dignity: An Ethical
Inquiry, Chapter 6; and the personal statements of Council
Members Robert George and Alfonso Gómez-Lobo, and William
Hurlbut in that same report.
89.
See, for instance, Steinberg, D., op. cit., pp. 49-50;
and Green, R., op. cit., p. 20.
90.
See, for instance, Meyer, M. J., and Nelson, L. J., "Respecting
What We Destroy: Reflections on Human Embryo Research,"
Hastings Center Report 31(1): 16-23 (2001).
91.
See, for instance, Strong, C., "The Moral Status of Preembryos,
Embryos, Fetuses, and Infants," The Journal of Medicine
and Philosophy 22(5): 457-478 (1997).
92.
Pearson, H., "Your Destiny, from Day One," Nature
418: 14-15 (2002).
93.
See, for instance, McCartney, J., op. cit., pp. 601-602;
Brogaard, B., "The moral status of the human embryo: the
twinning argument," Free Inquiry Winter 2002; Meyer,
M. J., op. cit., p. 18. The question of twinning-pro
and con-was also taken up by the Council in its July 2002
report, Human Cloning and Human Dignity: An Ethical Inquiry,
Chapter 6.
94.
See, for instance, Green , R., op. cit., pp. 21-22;
Lanza, R., op. cit., p. 3177.
95.
See, for instance, Ashley, B., and Moraczewski, A., "Cloning,
Aquinas, and the Embryonic Person," National Catholic
Bioethics Quarterly 1(2): 189-201 (2001); Orr, R., op.
cit., p. 58; Marquis, D., op. cit.; and Lori
Andrews quoted in Green, R., op. cit., p. 22. The
question of twinning-pro and con-was also taken up by the
Council in its July 2002 report, Human Cloning and Human
Dignity: An Ethical Inquiry, Chapter 6, and in the personal
statement of Council Member William Hurlbut, attached to
that report.
96.
See, for instance, National Bioethics Advisory Commission,
Ethical Issues in Human Stem cell research, Washington,
D.C.: Government Printing Office, 1999, p. 7; and the position
articulated by several Members of this Council in our July
2002 report Human Cloning and Human Dignity: An Ethical
Inquiry, Chapter 6, among many others.
97.
See, for instance, Lanza, R., op. cit., p. 3177.
98.
See, for instance, Strong, C., op. cit., p. 467.
99.
See, for instance, the views expressed by some Members of
this Council in our July 2002 report Human Cloning and
Human Dignity: An Ethical Inquiry, Chapter 6, and in
the personal statement of Council Members Robert George
and Alfonso Gómez-Lobo.
100.
See, for instance, the personal statement of Council Member
William Hurlbut, in the Council's July 2002 report Human
Cloning and Human Dignity: An Ethical Inquiry.
101.
See, for instance, Wilson, J., "On Abortion," Commentary
January 1994; and the position articulated by several Members
of this Council in our July 2002 report Human Cloning
and Human Dignity: An Ethical Inquiry, Chapter 6.
102.
See, for instance, Green, R., op. cit., pp. 20-30;
and the position articulated by several Members of this
Council in our July 2002 report Human Cloning and Human
Dignity: An Ethical Inquiry, Chapter 6.
103.
See, for instance, the views expressed by some Members of
this Council in our July 2002 report Human Cloning and
Human Dignity: An Ethical Inquiry, Chapter 6, and in
the personal statement of Council Members Robert George
and Alfonso Gómez-Lobo.
104.
See, for instance, National Institutes of Health, Report
of the Human Embryo Research Panel, Bethesda, MD.: NIH,
1994; and the position articulated by several Members of
this Council in our July 2002 report Human Cloning and
Human Dignity: An Ethical Inquiry, Chapter 6.
105.
See, for instance, McGee, G., "The Idolatry of Absolutizing
in the Stem Cell Debate," American Journal of Bioethics
2(1): 53-54 (2002).
106.
See, for instance, Green, R., op. cit., p. 20.
107.
See, for instance, the views expressed by some Members of
this Council in our July 2002 report Human Cloning and
Human Dignity: An Ethical Inquiry, Chapter 6, and in
the personal statements of Council Members Gilbert Meilaender,
William Hurlbut, Robert George and Alfonso Gómez-Lobo.
108.
"Report of the Ethics Advisory Board," 44 Fed. Reg.
35,033-35,058 (June 18, 1979) at 35,056.
109.
NIH, op. cit., Report of the Human Embryo Research
Panel, p. 2.
110.
National Bioethics Advisory Commission (NBAC), Ethical
Issues in Human Stem Cell Research Bethesda, MD.: Vol.
I, p. ii; cf. p. 2 (September 1999).
111.
See, for instance, Lebacqz, K., "On the Elusive Nature of
Respect," in Holland, S., Lebacqz K., and Zoloth, L., eds.,
The Human Embryonic Stem Cell Debate, Cambridge,
MA.: MIT Press, 2001, pp. 149-162; and the personal statement
of Council Member Rebecca Dresser, appended to the Council's
July 2002 report Human Cloning and Human Dignity: An
Ethical Inquiry.
112.
Hoffman, D.I., et al., "Cryopreserved Embryos in the United
States and Their Availability for Research," Fertility
and Sterility 79: 1063-1069 (2003).
113.
See, for instance, Spike, J., op. cit., p. 45.
114.
See, for instance, the testimony of Michael West before
the Labor, HHS, and Education Subcommittee of the Senate
Appropriations Committee, December 4, 2001, among others.
115.
Outka, G., "The Ethics of Stem cell research," a paper presented
to the Council for its April 2002 meeting, and available
on the Council website at www.bioethics.gov. A slightly
revised version appeared in the Kennedy Institute of
Ethics Journal, 12:2, pp. 175-213.
117.
See, for instance, "The Stem Cell Sell," Commonweal,
August 17, 2001; Meilaender, G., "Spare Embryos," The
Weekly Standard, August 26, 2002; and Council discussion
of Gene Outka's paper, in its April 2002 meeting, a transcript
of which is available on the Council website at www.bioethics.gov.
118.
See, for instance, McCartney, J, op. cit., p. 615.
119.
Council Member William Hurlbut, in Council communication.
120.
See, for instance, the comments of Council Member James
Wilson during Council discussion on April 25, 2002. The
full transcript is available on the Council's website at
www.bioethics.gov.
121.
A federal law, 42 U.S.C. § 289, is directed specifically
against any such lethal experimentation on these populations.
122.
This concern is raised in Outka, G., "The Ethics of Stem
Cell Research," a paper presented to the Council for its
April 2002 meeting, and available on the Council website
at www.bioethics.gov. Also see the Council discussion of
that paper, available on the Council website; and see Meilaender,
G., op. cit.
123.
See, for instance, the transcript of Council discussion
on April 25, 2002, available on the Council's website at
www.bioethics.gov.
124.
Guenin, L. M., "Morals and Primordials," Science
292: 1659-1660 (2001).
125.
Spike, J., op. cit., p. 45.
126.
Guenin, L., op. cit.
127.
See, for instance, Orr, R., op. cit., p. 58.
128.
Mahowald, M. and Mahwoald P., "Embryonic Stem Cell Retrieval
and a Possible Ethical Bypass," American Journal of Bioethics
2(1): 42-43 (2002).
129.
See, for instance, Zoloth, L., op. cit., pp. 4-5.
130.
See, for instance, Harris, J., "The ethical use of human
embryonic stem cells in research and therapy," in Burley,
J. and Harris, J., eds., A Companion to Genetics: Philosophy
and the Genetic Revolution, Oxford: Basil Blackwell,
2001; and Savulescu, J., "The Embryonic Stem Cell Lottery
and the Cannibalization of Human Beings," Bioethics 16(6):
508-529 (2002).
131.
This subject was discussed in a Council session on January
16, 2003. When asked, in the course of a presentation before
the Council, about the rate of natural embryo loss, Dr.
John Opitz (Professor of Pediatrics, Human Genetics, and
Obstetrics/Gynecology, School of Medicine, University of
Utah) responded: "Estimates range all the way from 60 percent
to 80 percent of the very earliest stages, cleavage stages,
for example, that are lost." The transcript of this session
is available on the Council website at www.bioethics.gov.
132.
Spike, J., op. cit., p. 45.
133.
Harris, J., "Stem Cells, Sex & Procreation," a paper
presented to the American Philosophical Society, March 29,
2003.
134.
Savulescu, J., op. cit., pp. 508-529.
135.
See, for instance, Orr, R., op. cit., pp. 57-59.
136.
See, for instance, Council discussion in its January 2003
meeting, a transcript of which is available on the Council
website at www.bioethics.gov.
137.
See, for instance, the comments of Rudolph Jaenisch before
the Council in its July 2003 meeting, and Dr. Jaenisch's
accompanying paper (included in Appendix N of this report).
See also the personal statement of Council Member Paul McHugh,
appended to the Council's July 2002 report Human Cloning
and Human Dignity: An Ethical Inquiry.
138.
See, for instance, Zoloth, L., op. cit., pp. 4-5.
139.
See, for instance, Mandavilli, A., "Fertility's New Frontier
Takes Shape in the Test Tube," Nature Medicine 9:
1095 (2003).
140.
See, for instance, Council discussion with Rudolph Jaenisch
at the Council's July 2003 meeting, and discussion taken
up in the Council's July 2002 report Human Cloning and
Human Dignity: An Ethical Inquiry, Chapter 6.
141.
See, for instance, the personal statement of Council Member
William Hurlbut, in the Council's July 2002 report Human
Cloning and Human Dignity: An Ethical Inquiry; the transcripts
of Council discussions on June 20, 2002 and July 24, 2003,
available on the Council's website at www.bioethics.gov;
and Weiss, R., "Can Scientists Bypass Stem Cells' Moral
Minefield?" The Washington Post, December 14, 1998,
p. A3.
142.
See, for instance, the transcript of Council discussion
on July 24, 2003, available on the Council's website at
www.bioethics.gov.
143.
See, for instance, the transcript of Council discussion
on June 20, 2002, available on the Council's website at
www.bioethics.gov.
144.
See remarks by Professor Rudolph Jaenisch before the Council's
July 24, 2003 meeting. A transcript of that session is available
on the Council's website at www.bioethics.gov.
145.
See, for instance, the personal statement of Council Member
William Hurlbut, in the Council's July 2002 report Human
Cloning and Human Dignity: An Ethical Inquiry.
146.
See, for instance, a number of arguments raised in Weiss,
R., "Can Scientists Bypass Stem Cells' Moral Minefield?"
The Washington Post, December 14, 1998, p. A3; and
the transcript of Council discussion on June 20, 2002, available
on the Council's website at www.bioethics.gov.
147.
Lauritzen, P., "Report on the Ethics of Stem cell research,"
a commissioned paper prepared at the request of the Council
and included in Appendix G of this report. See also the
Council's July 2002 report Human Cloning and Human Dignity:
An Ethical Inquiry, Chapter 6.
148.
See, for instance, Kass, L., "The Meaning of Life - In the
Laboratory," The Public Interest, Winter 2002. Also
see the Council's July 2002 report Human Cloning and
Human Dignity: An Ethical Inquiry, Chapter 6.
149.
This case is articulated by several Members of the Council
in the Council's July 2002 report Human Cloning and Human
Dignity: An Ethical Inquiry, Chapter 6. See also, "Biotechnology:
A House Divided," The Public Interest, Winter 2003.
150.
This case is articulated, for instance, by several Members
of the Council in the Council's July 2002 report Human
Cloning and Human Dignity: An Ethical Inquiry, Chapter
6.
151.
Strong, C., "Those Divisive Stem Cells: Dealing with Our
Most Contentious Issues," American Journal of Bioethics
2(1): 39-40 (2002).
152.
See, for instance, the Council's July 2002 report Human
Cloning and Human Dignity: An Ethical Inquiry, Chapters
6 and 8, available on the Council's website at www.bioethics.gov.
153.
See, for instance, Dresser, R., "Embryonic Stem Cells: Expanding
the Analysis," American Journal of Bioethics 2(1):
40-41 (2002); and FitzGerald, K., op. cit., pp. 50-51.
154.
Dresser, R., op. cit., p. 41.
156.
See also FitzGerald, K., op. cit., pp. 50-51.
157.
Dresser, R., op. cit., p. 41.
158.
See, for example, the discussion and presentations at the
Council's July 2003 meeting, available on the Council's
website at www.bioethics.gov.
159.
See, for instance, Orr, R., op. cit., pp. 57-58;
"A review of the National Institute of Health's Guidelines
for Research Using Human Pluripotent Stem Cells," Issues
in Law and Medicine 3(17): 293; and the testimony of
Representative David Weldon before the Technology and Space
Subcommittee of the Senate Commerce, Science and Transportation
Committee, January 29, 2003.
160.
Lauritzen, P., "Report on the Ethics of Stem cell research,"
a commissioned paper prepared at the request of the Council
and included in Appendix G of this report.
161.
See, for instance, Oldham, R., "Stem Cells: Private Sector
Can Do It Better," The Wall Street Journal, August
28, 2001, p. A14.
162.
See, for example, the discussion and presentations at the
Council's April 2002 meeting, available on the Council's
website at www.bioethics.gov; and Verfaillie, C., "Multipotent
Adult Progenitor Cells: An Update," a commissioned paper
prepared at the request of the Council and included in Appendix
J of this report.
163.
See, for example, the discussion and presentations at the
Council's July 2003 meeting, available on the Council's
website at www.bioethics.gov.
|
|
|